Item 9A. Controls and Procedures
Item 9A. Controls and Procedures
Healthcare Trust of America, Inc.
(a) Evaluation of disclosure controls and procedures. HTA’s management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in its reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management, including HTA’s Chief Executive Officer (as the principal executive officer) and HTA’s Chief Financial Officer (as the principal financial officer and principal accounting officer), to allow timely decisions regarding required disclosures.
As of December 31, 2021, an evaluation was conducted by HTA under the supervision and with the participation of its management, including HTA’s Chief Executive Officer and HTA’s Chief Financial Officer, of the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, HTA’s Chief Executive Officer and HTA’s Chief Financial Officer each concluded that HTA’s disclosure controls and procedures were effective as of December 31, 2021.
(b) Management’s report on internal control over financial reporting. HTA’s management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of HTA’s management, including its Chief Executive Officer and Chief Financial Officer, HTA conducted an evaluation of the effectiveness of its internal control over financial reporting based on the criteria in the 2013 Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this evaluation, HTA’s Interim Chief Executive Officer and HTA’s Chief Financial Officer concluded that HTA’s internal control over financial reporting was effective as of December 31, 2021.
Our independent registered public accounting firm, Deloitte & Touche LLP, independently assessed the effectiveness of HTA’s internal control over financial reporting. Deloitte & Touche LLP has issued a report, which is included at the end of Item 9A of this Annual Report.
65
Table of Contents
(c) Changes in internal control over financial reporting. There were no changes in our internal control over financial reporting that occurred during the year ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
March 1, 2022
Healthcare Trust of America Holdings, LP
(a) Evaluation of disclosure controls and procedures. HTALP’s management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in its reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management, including HTA’s Chief Executive Officer (as the principal executive officer) and HTA’s Chief Financial Officer (as the principal financial officer and principal accounting officer), to allow timely decisions regarding required disclosures.
As of December 31, 2021, an evaluation was conducted by HTALP under the supervision and with the participation of its management, including HTA’s Chief Executive Officer and HTA’s Chief Financial Officer, of the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, HTA’s Interim Chief Executive Officer and HTA’s Chief Financial Officer, on behalf of HTA in its capacity as general partner of HTALP, each concluded that HTALP’s disclosure controls and procedures were effective as of December 31, 2021.
(b) Management’s report on internal control over financial reporting. HTALP’s management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of its management, including HTA’s Chief Executive Officer and HTA’s Chief Financial Officer, HTALP conducted an evaluation of the effectiveness of its internal control over financial reporting based on the criteria in the 2013 Internal Control-Integrated Framework issued by COSO. Based on this evaluation, HTALP’s management, including HTA’s Chief Executive Officer and HTA’s Chief Financial Officer, concluded that HTALP’s internal control over financial reporting was effective as of December 31, 2021.
This Annual Report does not include an attestation report of HTALP’s independent registered public accounting firm, Deloitte & Touche LLP, pursuant to rules of the SEC applicable to “non-accelerated filers.”
(c) Changes in internal control over financial reporting. There were no changes in HTALP’s internal control over financial reporting that occurred during the year ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, HTALP’s internal control over financial reporting.
March 1, 2022
66
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of Healthcare Trust of America, Inc.
Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of Healthcare Trust of America, Inc. and subsidiaries (the “Company”) as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by COSO.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements and financial statement schedules as of and for the year ended December 31, 2021, of the Company and our report dated March 1, 2022, expressed an unqualified opinion on those financial statements.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ DELOITTE & TOUCHE LLP
Phoenix, Arizona
March 1, 2022
Item 9B. Other Information
None.
67
Table of Contents
PART III
Item 10. Directors, Executive Officers and Corporate Governance
The information required by this Item 10 will be set forth in the Proxy Statement and is incorporated herein by reference.
Item 11. Executive Compensation
The information required by this Item 11 will be set forth in the Proxy Statement and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item 12 will be set forth in the Proxy Statement and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this Item 13 will be set forth in the Proxy Statement and is incorporated herein by reference.
Item 14. Principal Accounting Fees and Services
The information required by this Item 14 will be set forth in the Proxy Statement and is incorporated herein by reference.
68
Table of Contents
PART IV
Item 15. Exhibits, Financial Statement Schedules
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Page
(a)(1) Financial Statements:
Reports of Independent Registered Public Accounting Firm (PCAOB ID: 34 )
Healthcare Trust of America, Inc.
71
Healthcare Trust of America Holdings, LP
73
Financial Statements of Healthcare Trust of America, Inc.
Consolidated Balance Sheets as of December 31, 202 1 and 20 20
75
Consolidated Statements of Operations for the Years Ended December 31, 202 1 , 20 20 and 201 9
76
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 202 1 , 20 20 and 201 9
77
Consolidated Statements of Equity for the Years Ended December 31, 202 1 , 20 20 and 201 9
78
Consolidated Statements of Cash Flows for the Years Ended December 31, 202 1 , 20 20 and 201 9
79
Financial Statements of Healthcare Trust of America Holdings, LP
Consolidated Balance Sheets as of December 31, 202 1 and 20 20
80
Consolidated Statements of Operations for the Years Ended December 31, 2021, 2020 and 2019
81
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2021, 2020 and 2019
82
Consolidated Statements of Changes in Partners’ Capital for the Years Ended December 31, 2021, 2020 and 2019
83
Consolidated Statements of Cash Flows for the Years Ended December 31, 2021, 2020 and 2019
84
Notes for Healthcare Trust of America, Inc. and Healthcare Trust of America Holdings, LP
Notes to Consolidated Financial Statements
85
(a)(2) Financial Statement Schedules:
Financial Statement Schedules of Healthcare Trust of America, Inc. and Healthcare Trust of America Holdings, LP
Real Estate and Accumulated Depreciation (Schedule III)
110
Mortgage Loans on Real Estate Assets (Schedule IV)
118
All other schedules have been omitted because they are inapplicable.
(a)(3) Exhibits:
The exhibits listed on the Exhibit Index (preceding the signature section of this Annual Report) are incorporated by reference into this Annual Report.
(b) Exhibits:
See Item 15(a)(1) above.
(c) Financial Statement Schedules:
See Item 15(a)(2) above.
69
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of Healthcare Trust of America, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Healthcare Trust of America, Inc. and subsidiaries (the “Company”) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income, equity, and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and the financial statement schedules listed in the Index at Item 15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 1, 2022, expressed an unqualified opinion on the Company’s internal control over financial reporting.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB .
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Recoverability of Real Estate and Real Estate Related Assets - Refer to Notes 2 and 4 to the financial statements
Critical Audit Matter Description
The Company’s real estate investments are evaluated for potential impairment whenever events or changes in circumstances indicate that the carrying value of a property may not be recoverable. Impairment losses are recorded when indicators of impairment are present and the carrying amount of the asset is greater than the sum of future undiscounted cash flows expected to be generated by that asset over the remaining expected holding period. The Company’s undiscounted future cash flows analysis and the assessment of expected remaining holding period requires management to make significant estimates and assumptions related to future occupancy levels, rental rates, lease-up periods and capitalization rates.
Changes in these assumptions could have a significant impact on the real estate assets identified for further analysis. For the year ended December 31, 2021, the Company recorded impairment charges of $22.9 million on its real estate investments.
Given the Company’s evaluation of the sum of future undiscounted cash flows expected to be generated by an asset over the remaining expected holding period when indicators of impairment are present requires management to make significant estimates and assumptions related to future occupancy levels, rental rates, and capitalization rates, performing audit procedures to evaluate the reasonableness of management’s undiscounted future cash flows analysis and assessment of expected remaining holding period required a high degree of auditor judgment and an increased extent of effort, including the need to involve our
70
Table of Contents
fair value specialists.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to the evaluation of real estate assets for possible indicators of impairment included the following, among others:
• We tested the effectiveness of controls over management’s analysis for impairment indicators, including the identification of impairment indicator properties and significant estimates and assumptions used by management in preparing undiscounted future cash flows analysis for properties with impairment indicators.
• We audited management’s impairment indicator analysis by:
◦ Evaluating management's process for identifying impairment indicators and whether management appropriately considered the examples of impairment indicators provided within the Financial Accounting Standards Board’s (FASB) Accounting Standard Codification (ASC) 360, Property, Plant, and Equipment .
◦ Conducting independent market analysis to determine if there were additional indicators of impairment not identified by management.
◦ Conducting inquiries of property management, leasing, asset management, and other departments outside of the accounting department to determine if there might be additional indicators of impairment not identified by management.
• With the assistance of our fair value specialists, we evaluated management’s undiscounted cash flow analysis for various properties that exhibited indicators of impairment by:
◦ Evaluating whether the valuation method used was in accordance with ASC 820, Fair Value Measurement .
◦ Evaluating the undiscounted future cash flows analysis, including estimates of future occupancy levels, rental rates, lease-up periods and capitalization rates, in addition to the assessment of expected remaining holding period for each real estate asset with possible impairment indicators by (1) evaluating the source information and assumptions used by management and (2) testing the mathematical accuracy of the undiscounted future cash flows analysis.
Investments in Real Estate - Refer to Notes 2 and 3 to the financial statements
Critical Audit Matter Description
For the year ended December 31, 2021, the Company had acquired investments in real estate with an aggregate purchase price of $308.8 million. The Company accounted for these acquisitions as asset acquisitions. Accordingly, the purchase price for assets acquired and liabilities assumed was allocated, based on relative fair value, to land, buildings and improvements, in-place leases, above or below market leases, and other intangible assets. The method for determining relative fair value varied depending on the type of asset or liability and involved management making significant estimates related to assumptions such as future cash flows, discount rates, and costs during the expected lease-up periods.
Given the relative fair value determination of assets acquired and liabilities assumed requires management to make significant estimates related to assumptions such as future cash flows, discount rates, and costs during hypothetical lease-up periods, performing audit procedures to evaluate the reasonableness of these assumptions required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to the relative fair value of assets acquired and liabilities assumed for investments in real estate included the following, among others:
• We tested the effectiveness of controls over the purchase price allocation, including management’s controls over the review of purchase price allocations prepared by third party specialists.
• For properties selected for further evaluation by our fair value specialists, we evaluated the reasonableness of the (1) valuation methodology, (2) current market data, (3) cost to replace certain assets, and (4) assumptions used in the discounted cash flows, including testing the mathematical accuracy of the calculation, and developing a range of independent estimates and comparing our estimates to those used by management.
• We assessed the reasonableness of management’s projections of rental revenue by comparing the assumptions used in the projections to external market sources, in-place lease agreements, historical data, and results from other areas of the audit.
/s/ DELOITTE & TOUCHE LLP
Phoenix, Arizona
March 1, 2022
We have served as the Company’s auditor since 2006.
71
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Partners and the Board of Directors of the General Partner of Healthcare Trust of America Holdings, LP
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Healthcare Trust of America Holdings, LP and subsidiaries (the “Company”) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income, changes in partners’ capital, and cash flows, for each of the three years in the period ended December 31, 2021, and the related notes and the financial statement schedules listed in the Index at Item 15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Recoverability of Real Estate and Real Estate Related Assets - Refer to Notes 2 and 4 to the financial statements
Critical Audit Matter Description
The Company’s real estate investments are evaluated for potential impairment whenever events or changes in circumstances indicate that the carrying value of a property may not be recoverable. Impairment losses are recorded when indicators of impairment are present and the carrying amount of the asset is greater than the sum of future undiscounted cash flows expected to be generated by that asset over the remaining expected holding period. The Company’s undiscounted future cash flows analysis and the assessment of expected remaining holding period requires management to make significant estimates and assumptions related to future occupancy levels, rental rates, lease-up periods and capitalization rates.
Changes in these assumptions could have a significant impact on the real estate assets identified for further analysis. For the year ended December 31, 2021, the Company recorded impairment charges of $22.9 million on its real estate investments.
Given the Company’s evaluation of the sum of future undiscounted cash flows expected to be generated by an asset over the remaining expected holding period when indicators of impairment are present requires management to make significant estimates and assumptions related to future occupancy levels, rental rates, and capitalization rates, performing audit procedures to evaluate the reasonableness of management’s undiscounted future cash flows analysis and assessment of expected remaining holding period required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.
72
Table of Contents
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to the evaluation of real estate assets for possible indicators of impairment included the following, among others:
• We tested the effectiveness of controls over management’s analysis for impairment indicators, including the identification of impairment indicator properties and significant estimates and assumptions used by management in preparing undiscounted future cash flows analysis for properties with impairment indicators.
• We audited management’s impairment indicator analysis by:
◦ Evaluating management's process for identifying impairment indicators and whether management appropriately considered the examples of impairment indicators provided within the Financial Accounting Standards Board’s (FASB) Accounting Standard Codification (ASC) 360, Property, Plant, and Equipment .
◦ Conducting independent market analysis to determine if there were additional indicators of impairment not identified by management.
◦ Conducting inquiries of property management, leasing, asset management, and other departments outside of the accounting department to determine if there might be additional indicators of impairment not identified by management.
• With the assistance of our fair value specialists, we evaluated management’s undiscounted cash flow analysis for various properties that exhibited indicators of impairment by:
◦ Evaluating whether the valuation method used was in accordance with ASC 820, Fair Value Measurement .
◦ Evaluating the undiscounted future cash flows analysis, including estimates of future occupancy levels, rental rates, lease-up periods and capitalization rates, in addition to the assessment of expected remaining holding period for each real estate asset with possible impairment indicators by (1) evaluating the source information and assumptions used by management and (2) testing the mathematical accuracy of the undiscounted future cash flows analysis.
Investments in Real Estate - Refer to Notes 2 and 3 to the financial statements
Critical Audit Matter Description
For the year ended December 31, 2021, the Company had acquired investments in real estate with an aggregate purchase price of $308.8 million. The Company accounted for these acquisitions as asset acquisitions. Accordingly, the purchase price for assets acquired and liabilities assumed was allocated based on relative fair value, to land, buildings and improvements, in-place leases, above or below market leases, and other intangible assets. The method for determining relative fair value varied depending on the type of asset or liability and involved management making significant estimates related to assumptions such as future cash flows, discount rates, and costs during the expected lease-up periods.
Given the relative fair value determination of assets acquired and liabilities assumed requires management to make significant estimates related to assumptions such as future cash flows, discount rates, and costs during hypothetical lease-up periods, performing audit procedures to evaluate the reasonableness of these assumptions required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to the relative fair value of assets acquired and liabilities assumed for investments in real estate included the following, among others:
• We tested the effectiveness of controls over the purchase price allocation, including management’s controls over the review of purchase price allocations prepared by third party specialists.
• For properties selected for further evaluation by our fair value specialists, we evaluated the reasonableness of the (1) valuation methodology, (2) current market data, (3) cost to replace certain assets, and (4) assumptions used in the discounted cash flows, including testing the mathematical accuracy of the calculation, and developing a range of independent estimates and comparing our estimates to those used by management.
• We assessed the reasonableness of management’s projections of rental revenue by comparing the assumptions used in the projections to external market sources, in-place lease agreements, historical data, and results from other areas of the audit.
/s/ DELOITTE & TOUCHE LLP
Phoenix, Arizona
March 1, 2022
We have served as the Company’s auditor since 2013.
73
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except for share and per share data)
December 31,
2021 2020
ASSETS
Real estate investments:
Land $ 640,382 $ 596,269
Building and improvements 6,688,516 6,507,816
Lease intangibles 404,714 628,621
Construction in progress 32,685 80,178
7,766,297 7,812,884
Accumulated depreciation and amortization ( 1,598,468 ) ( 1,702,719 )
Real estate investments, net
6,167,829 6,110,165
Assets held for sale, net 27,070 —
Investment in unconsolidated joint venture 62,834 64,360
Cash and cash equivalents 52,353 115,407
Restricted cash 4,716 3,358
Receivables and other assets, net 334,941 251,728
Right-of-use assets - operating leases, net 229,226 235,223
Other intangibles, net 10,720 10,451
Total assets $ 6,889,689 $ 6,790,692
LIABILITIES AND EQUITY
Liabilities:
Debt $ 3,028,122 $ 3,026,999
Accounts payable and accrued liabilities 198,078 200,358
Liabilities of assets held for sale 262 —
Derivative financial instruments - interest rate swaps 5,069 14,957
Security deposits, prepaid rent and other liabilities 86,225 82,553
Lease liabilities - operating leases 196,286 198,367
Intangible liabilities, net 31,331 32,539
Total liabilities 3,545,373 3,555,773
Commitments and contingencies
Redeemable non-controlling interests — —
Equity:
Preferred stock, $ 0.01 par value; 200,000,000 shares authorized; none issued and outstanding
— —
Common stock, $ 0.01 par value; 1,000,000,000 shares authorized; 228,879,846 and 218,578,012 shares issued and outstanding as of December 31, 2021 and 2020, respectively
2,289 2,186
Additional paid-in capital 5,178,132 4,916,784
Accumulated other comprehensive loss ( 7,041 ) ( 16,979 )
Cumulative dividends in excess of earnings ( 1,915,776 ) ( 1,727,752 )
Total stockholders’ equity 3,257,604 3,174,239
Non-controlling interests 86,712 60,680
Total equity 3,344,316 3,234,919
Total liabilities and equity $ 6,889,689 $ 6,790,692
The accompanying notes are an integral part of these consolidated financial statements.
74
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except for per share data)
Year Ended December 31,
2021 2020 2019
Revenues:
Rental income $ 763,923 $ 738,414 $ 691,527
Interest and other operating income
3,150 551 513
Total revenues 767,073 738,965 692,040
Expenses:
Rental 236,850 226,859 211,479
General and administrative 49,744 42,969 41,360
Transaction 372 965 2,350
Depreciation and amortization 303,834 303,828 290,384
Interest expense 92,762 94,613 96,632
Impairment 22,938 — —
Total expenses 706,500 669,234 642,205
Gain (loss) on sale of real estate, net 39,228 9,590 ( 154 )
Loss on sale of corporate asset, net ( 2,106 ) — —
Loss on extinguishment of debt, net — ( 27,726 ) ( 21,646 )
Income from unconsolidated joint venture 1,604 1,612 1,882
Other income 485 301 841
Net income $ 99,784 $ 53,508 $ 30,758
Net income attributable to non-controlling interests (1)
( 1,768 ) ( 890 ) ( 604 )
Net income attributable to common stockholders $ 98,016 $ 52,618 $ 30,154
Earnings per common share - basic:
Net income attributable to common stockholders
$ 0.45 $ 0.24 $ 0.15
Earnings per common share - diluted:
Net income attributable to common stockholders
$ 0.44 $ 0.24 $ 0.14
Weighted average common shares outstanding:
Basic 219,439 218,078 205,720
Diluted 224,215 221,666 209,605
(1) Includes amounts attributable to redeemable non-controlling interests for 2019.
The accompanying notes are an integral part of these consolidated financial statements.
75
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
Year Ended December 31,
2021 2020 2019
Net income $ 99,784 $ 53,508 $ 30,758
Other comprehensive income (loss)
Change in unrealized gains (losses) on cash flow hedges 10,114 ( 21,876 ) 4,316
Total other comprehensive (loss) income 10,114 ( 21,876 ) 4,316
Total comprehensive income 109,898 31,632 35,074
Comprehensive income attributable to non-controlling interests ( 1,944 ) ( 539 ) ( 615 )
Total comprehensive income attributable to common stockholders
$ 107,954 $ 31,093 $ 34,459
The accompanying notes are an integral part of these consolidated financial statements.
76
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC.
CONSOLIDATED STATEMENTS OF EQUITY
(In thousands)
Common Stock Additional Paid-In Capital Accumulated Other Comprehensive Income (Loss) Cumulative Dividends in Excess of Earnings Total Stockholders’ Equity Non-controlling Interests Total Equity
Shares Amount
Balance as of December 31, 2018 205,267 $ 2,053 $ 4,525,969 $ 307 $ ( 1,272,305 ) $ 3,256,024 $ 78,890 $ 3,334,914
Issuance of common stock, net 11,096 112 322,106 — — 322,218 — 322,218
Issuance of OP Units in HTALP 2,603 2,603
Issuance of limited partner OP Units in connection with acquisitions — — — — — — 2,000 2,000
Share-based award transactions, net 319 3 10,124 — — 10,127 — 10,127
Repurchase and cancellation of common stock ( 487 ) ( 5 ) ( 12,173 ) — — ( 12,178 ) — ( 12,178 )
Redemption of non-controlling interest and other 258 2 8,016 — — 8,018 ( 6,293 ) 1,725
Dividends declared ($ 1.250 per common share)
— — — — ( 260,593 ) ( 260,593 ) ( 5,180 ) ( 265,773 )
Net income — — — — 30,154 30,154 538 30,692
Other comprehensive income — — — 4,239 4,239 77 4,316
Balance as of December 31, 2019 216,453 2,165 4,854,042 4,546 ( 1,502,744 ) 3,358,009 72,635 3,430,644
Issuance of common stock, net 1,675 17 50,003 — — 50,020 — 50,020
Issuance of OP Units in HTALP — — — — — — 1,378 1,378
Share-based award transactions, net 263 3 8,913 — — 8,916 — 8,916
Repurchase and cancellation of common stock ( 174 ) ( 2 ) ( 5,190 ) — — ( 5,192 ) — ( 5,192 )
Redemption of non-controlling interest and other 361 3 9,016 — — 9,019 ( 9,019 ) —
Dividends declared ($ 1.270 per common share)
— — — — ( 277,626 ) ( 277,626 ) ( 4,853 ) ( 282,479 )
Net income — — — — 52,618 52,618 890 53,508
Other comprehensive loss — — — ( 21,525 ) — ( 21,525 ) ( 351 ) ( 21,876 )
Balance as of December 31, 2020 218,578 2,186 4,916,784 ( 16,979 ) ( 1,727,752 ) 3,174,239 60,680 3,234,919
Issuance of common stock, net 9,419 94 251,156 — — 251,250 — 251,250
Issuance of OP Units in HTALP — — — — — — 35,785 35,785
Share-based award transactions, net 391 4 7,258 — — 7,262 — 7,262
Repurchase and cancellation of common stock ( 125 ) ( 1 ) ( 3,413 ) — — ( 3,414 ) — ( 3,414 )
Redemption of non-controlling interest and other 617 6 6,347 — — 6,353 ( 6,353 ) —
Dividends declared ($ 1.290 per common share)
— — — — ( 286,040 ) ( 286,040 ) ( 5,344 ) ( 291,384 )
Net income — — — — 98,016 98,016 1,768 99,784
Other comprehensive income — — — 9,938 — 9,938 176 10,114
Balance as of December 31, 2021 228,880 $ 2,289 $ 5,178,132 $ ( 7,041 ) $ ( 1,915,776 ) $ 3,257,604 $ 86,712 $ 3,344,316
The accompanying notes are an integral part of these consolidated financial statements.
77
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Year Ended December 31,
2021 2020 2019
Cash flows from operating activities:
Net income $ 99,784 $ 53,508 $ 30,758
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
283,300 283,039 280,969
Share-based compensation expense 7,262 8,916 10,127
Impairment 22,938 — —
Income from unconsolidated joint venture ( 1,604 ) ( 1,612 ) ( 1,882 )
Distributions from unconsolidated joint venture 3,130 3,240 3,030
(Gain) loss on sale of real estate, net ( 39,228 ) ( 9,590 ) 154
Loss on sale of corporate asset, net 2,106 — —
Loss on extinguishment of debt, net — 27,726 21,646
Changes in operating assets and liabilities:
Receivables and other assets, net ( 4,699 ) ( 11,042 ) ( 12,857 )
Accounts payable and accrued liabilities 9,430 2,066 ( 128 )
Prepaid rent and other liabilities 3,197 31,711 8,577
Net cash provided by operating activities 385,616 387,962 340,394
Cash flows from investing activities:
Investments in real estate ( 264,340 ) ( 185,286 ) ( 553,298 )
Development of real estate ( 63,306 ) ( 77,077 ) ( 28,066 )
Proceeds from the sale of real estate 87,628 22,939 4,880
Proceeds from the sale of corporate assets 10,127 — —
Capital expenditures ( 97,155 ) ( 74,743 ) ( 91,544 )
Other investment ( 6,000 ) — —
Collection of real estate notes receivable 15,405 907 739
Advances on real estate notes receivable ( 82,214 ) ( 6,000 ) —
Net cash used in investing activities ( 399,855 ) ( 319,260 ) ( 667,289 )
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility 310,000 1,329,862 610,000
Payments on unsecured revolving credit facility ( 310,000 ) ( 1,429,862 ) ( 510,000 )
Proceeds from unsecured senior notes — 793,568 906,927
Payments on unsecured senior notes — ( 300,000 ) ( 700,000 )
Payments on secured mortgage loans — ( 114,060 ) ( 97,361 )
Deferred financing costs ( 8,053 ) ( 6,800 ) ( 7,776 )
Debt extinguishment costs — ( 25,939 ) ( 18,383 )
Proceeds from issuance of common stock 251,250 50,020 323,393
Issuance of OP Units — 1,378 —
Repurchase and cancellation of common stock ( 3,414 ) ( 5,192 ) ( 12,178 )
Dividends paid ( 281,820 ) ( 275,816 ) ( 256,117 )
Distributions paid to non-controlling interest of limited partners ( 5,420 ) ( 4,712 ) ( 8,758 )
Sale of non-controlling interest — — 1,234
Net cash (used in) provided by financing activities ( 47,457 ) 12,447 230,981
Net change in cash, cash equivalents and restricted cash ( 61,696 ) 81,149 ( 95,914 )
Cash, cash equivalents and restricted cash - beginning of year 118,765 37,616 133,530
Cash, cash equivalents and restricted cash - end of year $ 57,069 $ 118,765 $ 37,616
The accompanying notes are an integral part of these consolidated financial statements.
78
Table of Contents
HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
CONSOLIDATED BALANCE SHEETS
(In thousands, except unit data)
December 31,
2021 2020
ASSETS
Real estate investments:
Land $ 640,382 $ 596,269
Building and improvements 6,688,516 6,507,816
Lease intangibles 404,714 628,621
Construction in progress 32,685 80,178
7,766,297 7,812,884
Accumulated depreciation and amortization ( 1,598,468 ) ( 1,702,719 )
Real estate investments, net
6,167,829 6,110,165
Assets held for sale, net 27,070 —
Investment in unconsolidated joint venture 62,834 64,360
Cash and cash equivalents 52,353 115,407
Restricted cash 4,716 3,358
Receivables and other assets, net 334,941 251,728
Right-of-use assets - operating leases, net 229,226 235,223
Other intangibles, net 10,720 10,451
Total assets $ 6,889,689 $ 6,790,692
LIABILITIES AND PARTNERS’ CAPITAL
Liabilities:
Debt $ 3,028,122 $ 3,026,999
Accounts payable and accrued liabilities 198,078 200,358
Liabilities of assets held for sale 262 —
Derivative financial instruments - interest rate swaps 5,069 14,957
Security deposits, prepaid rent and other liabilities 86,225 82,553
Lease liabilities - operating leases 196,286 198,367
Intangible liabilities, net 31,331 32,539
Total liabilities 3,545,373 3,555,773
Commitments and contingencies
Redeemable non-controlling interests — —
Partners’ Capital:
Limited partners’ capital, 4,142,408 and 3,519,545 OP Units issued and outstanding as of December 31, 2021 and 2020, respectively
86,442 60,410
General partners’ capital, 228,879,846 and 218,578,012 OP Units issued and outstanding as of December 31, 2021 and 2020, respectively
3,257,874 3,174,509
Total partners’ capital 3,344,316 3,234,919
Total liabilities and partners’ capital $ 6,889,689 $ 6,790,692
The accompanying notes are an integral part of these consolidated financial statements.
79
Table of Contents
HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per unit data)
Year Ended December 31,
2021 2020 2019
Revenues:
Rental income $ 763,923 $ 738,414 $ 691,527
Interest and other operating income
3,150 551 513
Total revenues 767,073 738,965 692,040
Expenses:
Rental 236,850 226,859 211,479
General and administrative 49,744 42,969 41,360
Transaction 372 965 2,350
Depreciation and amortization 303,834 303,828 290,384
Interest expense 92,762 94,613 96,632
Impairment 22,938 — —
Total expenses 706,500 669,234 642,205
Gain (loss) on sale of real estate, net 39,228 9,590 ( 154 )
Loss on sale of corporate asset, net ( 2,106 ) — —
Loss on extinguishment of debt, net — ( 27,726 ) ( 21,646 )
Income from unconsolidated joint venture 1,604 1,612 1,882
Other income 485 301 841
Net income $ 99,784 $ 53,508 $ 30,758
Net income attributable to non-controlling interests — — ( 66 )
Net income attributable to common OP unitholders $ 99,784 $ 53,508 $ 30,692
Earnings per common OP unit - basic:
Net income attributable to common OP unitholders $ 0.45 $ 0.24 $ 0.15
Earnings per common OP unit - diluted:
Net income attributable to common OP unitholders $ 0.45 $ 0.24 $ 0.15
Weighted average common OP units outstanding:
Basic 223,299 221,666 209,605
Diluted 224,215 221,666 209,605
The accompanying notes are an integral part of these consolidated financial statements.
80
Table of Contents
HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
Year Ended December 31,
2021 2020 2019
Net income $ 99,784 $ 53,508 $ 30,758
Other comprehensive income (loss)
Change in unrealized gains (losses) on cash flow hedges 10,114 ( 21,876 ) 4,316
Total other comprehensive income (loss) 10,114 ( 21,876 ) 4,316
Total comprehensive income 109,898 31,632 35,074
Comprehensive income attributable to non-controlling interests — — ( 66 )
Total comprehensive income attributable to common unitholders
$ 109,898 $ 31,632 $ 35,008
The accompanying notes are an integral part of these consolidated financial statements.
81
Table of Contents
HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
CONSOLIDATED STATEMENTS OF CHANGES IN PARTNERS ’ CAPITAL
(In thousands)
General Partners’ Capital Limited Partners’ Capital Total Partners’ Capital
Units Amount Units Amount
Balance as of December 31, 2018 205,267 $ 3,256,294 3,929 $ 78,620 $ 3,334,914
Issuance of general partner OP Units, net
11,096 322,218 — — 322,218
Issuance of limited partner OP Units — — — 2,603 2,603
Issuance of limited partner OP Units in connection with an acquisition
— — 163 2,000 2,000
Share-based award transactions, net
319 10,127 — — 10,127
Redemption and cancellation of general partner OP Units
( 487 ) ( 12,178 ) — — ( 12,178 )
Redemption of limited partner OP Units and other
258 8,018 ( 258 ) ( 6,293 ) 1,725
Distributions declared ($ 1.250 per common unit)
— ( 260,593 ) — ( 5,180 ) ( 265,773 )
Net income — 30,154 — 538 30,692
Other comprehensive income — 4,239 — 77 4,316
Balance as of December 31, 2019 216,453 3,358,279 3,834 72,365 3,430,644
Issuance of general partner OP Units, net
1,675 50,020 — — 50,020
Issuance of limited partner OP Units — — 47 1,378 1,378
Share-based award transactions, net
263 8,916 — — 8,916
Redemption and cancellation of general partner OP Units
( 174 ) ( 5,192 ) — — ( 5,192 )
Redemption of limited partner OP Units and other
361 9,019 ( 361 ) ( 9,019 ) —
Distributions declared ($ 1.270 per common unit)
— ( 277,626 ) — ( 4,853 ) ( 282,479 )
Net income — 52,618 — 890 53,508
Other comprehensive loss — ( 21,525 ) — ( 351 ) ( 21,876 )
Balance as of December 31, 2020 218,578 3,174,509 3,520 60,410 3,234,919
Issuance of general partner OP Units, net
9,419 251,250 — — 251,250
Issuance of limited partner OP Units in connection with acquisitions
— — 1,239 35,785 35,785
Share-based award transactions, net
391 7,262 — — 7,262
Redemption and cancellation of general partner OP Units
( 125 ) ( 3,414 ) — — ( 3,414 )
Redemption of limited partner OP Units and other
617 6,353 ( 617 ) ( 6,353 ) —
Distributions declared ($ 1.290 per common unit)
— ( 286,040 ) — ( 5,344 ) ( 291,384 )
Net income
— 98,016 — 1,768 99,784
Other comprehensive income — 9,938 — 176 10,114
Balance as of December 31, 2021 228,880 $ 3,257,874 4,142 $ 86,442 $ 3,344,316
The accompanying notes are an integral part of these consolidated financial statements.
82
Table of Contents
HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Year Ended December 31,
2021 2020 2019
Cash flows from operating activities:
Net income $ 99,784 $ 53,508 $ 30,758
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
283,300 283,039 280,969
Share-based compensation expense 7,262 8,916 10,127
Impairment 22,938 — —
Income from unconsolidated joint venture ( 1,604 ) ( 1,612 ) ( 1,882 )
Distributions from unconsolidated joint venture 3,130 3,240 3,030
(Gain) loss on sale of real estate, net ( 39,228 ) ( 9,590 ) 154
Loss on sale of corporate asset, net 2,106 — —
Loss on extinguishment of debt, net — 27,726 21,646
Changes in operating assets and liabilities:
Receivables and other assets, net ( 4,699 ) ( 11,042 ) ( 12,857 )
Accounts payable and accrued liabilities 9,430 2,066 ( 128 )
Prepaid rent and other liabilities 3,197 31,711 8,577
Net cash provided by operating activities 385,616 387,962 340,394
Cash flows from investing activities:
Investments in real estate ( 264,340 ) ( 185,286 ) ( 553,298 )
Development of real estate ( 63,306 ) ( 77,077 ) ( 28,066 )
Proceeds from the sale of real estate 87,628 22,939 4,880
Proceeds from the sale of corporate assets 10,127 — —
Capital expenditures ( 97,155 ) ( 74,743 ) ( 91,544 )
Other investment ( 6,000 ) — —
Collection of real estate notes receivable 15,405 907 739
Advances on real estate notes receivable ( 82,214 ) ( 6,000 ) —
Net cash used in investing activities ( 399,855 ) ( 319,260 ) ( 667,289 )
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility 310,000 1,329,862 610,000
Payments on unsecured revolving credit facility ( 310,000 ) ( 1,429,862 ) ( 510,000 )
Proceeds from unsecured senior notes — 793,568 906,927
Payments on unsecured senior notes — ( 300,000 ) ( 700,000 )
Payments on secured mortgage loans — ( 114,060 ) ( 97,361 )
Deferred financing costs ( 8,053 ) ( 6,800 ) ( 7,776 )
Debt extinguishment costs — ( 25,939 ) ( 18,383 )
Proceeds from issuance of general partner OP units 251,250 50,020 323,393
Issuance of limited partner OP units — 1,378 —
Repurchase and cancellation of general partner OP units ( 3,414 ) ( 5,192 ) ( 12,178 )
Distributions paid to general partner ( 281,820 ) ( 275,816 ) ( 256,117 )
Distributions paid to limited partners and redeemable non-controlling interests ( 5,420 ) ( 4,712 ) ( 8,758 )
Sale of non-controlling interest — — 1,234
Net cash (used in) provided by financing activities ( 47,457 ) 12,447 230,981
Net change in cash, cash equivalents and restricted cash ( 61,696 ) 81,149 ( 95,914 )
Cash, cash equivalents and restricted cash - beginning of year 118,765 37,616 133,530
Cash, cash equivalents and restricted cash - end of year $ 57,069 $ 118,765 $ 37,616
The accompanying notes are an integral part of these consolidated financial statements.
83
Table of Contents
Unless otherwise indicated or unless the context requires otherwise the use of the words “we,” “us” or “our” refers to Healthcare Trust of America, Inc. and Healthcare Trust of America Holdings, LP, collectively.
1. Organization and Description of Business
HTA, a Maryland corporation, and HTALP, a Delaware limited partnership, were incorporated or formed, as applicable, on April 20, 2006. HTA operates as a REIT and is the general partner of HTALP, which is the operating partnership, in an umbrella partnership, or “UPREIT” structure. HTA has qualified and intends to continue to be taxed as a REIT for federal income tax purposes under the applicable sections of the Internal Revenue Code.
We own real estate primarily consisting of MOBs located on or adjacent to hospital campuses or in off-campus, community core outpatient locations across 32 states within the U.S., and we lease space to tenants primarily consisting of health systems, research and academic institutions, and various sized physician practices. We generate substantially all of our revenues from rents and rental-related activities, such as property and facilities management and other incidental revenues related to the operation of real estate.
Our primary objective is to maximize stockholder value with growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we: (i) seek internal growth through proactive asset management, leasing, building services and property management oversight; (ii) target accretive acquisitions and developments of MOBs in markets with attractive demographics that complement our existing portfolio; and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage. Additionally, from time to time we consider, on an opportunistic basis, significant portfolio acquisitions that we believe fit our core business and we expect to enhance our existing portfolio.
COVID-19 Pandemic
On March 11, 2020 the novel coronavirus disease (“COVID-19”) was declared a pandemic by the World Health Organization. As the virus continued to spread throughout the United States and other countries across the world, Federal, state and local governments took various actions including the issuance of “stay-at-home” orders, social distancing guidelines and ordering the temporary closure of non-essential businesses to limit the spread of COVID-19. While many businesses have reopened and vaccinations are becoming more widely available to the general population, the economic uncertainty created by the COVID-19 pandemic continue to present risks to the Company and the future results of our operations. Although we did not experience significant disruptions from the COVID-19 pandemic during the year ended December 31, 2021, should current and planned measures, including further development and delivery of vaccines and other measures intended to reduce or eliminate the spread of COVID-19, past and/or proposed economic stimulus, and other laws, acts and orders proposed or enacted by these various governmental agencies ultimately not be successful or limited in their efficacy, our business and the broader real estate industry may experience significant adverse consequences. These consequences include loss of revenues, increased expenses, increased costs of materials, difficulty in maintaining an active workforce, and constraints on our ability to secure capital or financing, among other factors.
2. Summary of Significant Accounting Policies
The summary of significant accounting policies presented below is designed to assist in understanding our consolidated financial statements. Such consolidated financial statements and the accompanying notes are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to GAAP in all material respects and have been consistently applied in preparing our accompanying consolidated financial statements.
Basis of Presentation
Our accompanying consolidated financial statements include our accounts and those of our subsidiaries and any consolidated VIEs. All inter-company balances and transactions have been eliminated in the accompanying consolidated financial statements .
Principles of Consolidation
The consolidated financial statements include the accounts of our subsidiaries and consolidated joint venture arrangements. The portions of the HTALP operating partnership not owned by us are presented as non-controlling interests in our consolidated balance sheets and statements of operations, consolidated statements of comprehensive income or loss, consolidated statements of equity, and consolidated statements of changes in partners’ capital. The portions of other joint venture arrangements not owned by us are presented as redeemable non-controlling interests on the accompanying consolidated balance sheets. Holders of OP Units are considered to be non-controlling interest holders in HTALP and their ownership interests are reflected as equity on the accompanying consolidated balance sheets. Further, a portion of the earnings and losses of HTALP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion
84
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
of OP Units to common stock, any difference between the fair value of the common stock issued and the carrying value of the OP Units converted to common stock is recorded as a component of equity. As of December 31, 2021, 2020 and 2019, there were approximately 4.1 million, 3.5 million and 3.8 million, respectively, of OP Units issued and outstanding.
VIEs are entities where investors lack sufficient equity at risk for the entity to finance its activities without additional subordinated financial support or where equity investors, as a group, lack one of the following: (i) the power to direct the activities that most significantly impact the entity’s economic performance; (ii) the obligation to absorb the expected losses of the entity; and (iii) the right to receive the expected returns of the entity. We consolidate our investment in VIEs when we determine that we are the primary beneficiary. A primary beneficiary is one that has both: (i) the power to direct the activities of the VIE that most significantly impacts the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The HTALP operating partnership and our other joint venture arrangements are VIEs because the limited partners in those partnerships, although entitled to vote on certain matters, do not possess kick-out rights or substantive participating rights. Additionally, we determined that we are the primary beneficiary of our VIEs. Accordingly, we consolidate our interests in the HTALP operating partnership and in our other joint venture arrangements. However, because we hold what is deemed a majority voting interest in the HTALP operating partnership and our other joint venture arrangements, it qualifies for the exemption from providing certain disclosure requirements associated with investments in VIEs. We will evaluate on an ongoing basis the need to consolidate entities based on the standards set forth in GAAP as described above.
Use of Estimates
The preparation of our consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. These estimates are made and evaluated on an ongoing basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates, perhaps in adverse ways, and those estimates could be different under different assumptions or conditions.
Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents consist of all highly liquid investments with a maturity of three months or less when purchased. Restricted cash is comprised of (i) reserve accounts for property taxes, insurance, capital improvements and tenant improvements; (ii) collateral accounts for debt and interest rate swaps; and (iii) deposits for future investments.
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying consolidated balance sheets to the combined amounts shown on the accompanying consolidated statements of cash flows (in thousands):
December 31,
2021 2020 2019
Cash and cash equivalents $ 52,353 $ 115,407 $ 32,713
Restricted cash 4,716 3,358 4,903
Total cash, cash equivalents and restricted cash $ 57,069 $ 118,765 $ 37,616
Revenue Recognition
Minimum annual rental revenue is recognized on a straight-line basis over the term of the related lease (including rent holidays). Differences between rental income recognized and amounts contractually due under the lease agreements are recorded as straight-line rent receivables. If we determine that collectability of future minimum lease payments is not probable, the straight-line rent receivable balance is written off and recognized as a decrease in revenue in that period. Tenant reimbursement revenue, which is comprised of additional amounts recoverable from tenants for real estate taxes, common area maintenance and other certain operating expenses are recognized as revenue on a gross basis in the period in which the related recoverable expenses are incurred. We accrue revenue corresponding to these expenses on a quarterly basis to adjust recorded amounts to our best estimate of the final annual amounts to be billed. Subsequent to year-end, on a calendar year basis, we perform reconciliations on a lease-by-lease basis and bill or credit each tenant for any differences between the estimated expenses we billed and the actual expenses that were incurred. We recognize lease termination fees when there is a signed termination letter agreement, all of the conditions of the agreement have been met, and the tenant is no longer occupying the property. Rental income is reported net of amortization of inducements.
Effective January 1, 2018, with the adoption of Topic 606 - Revenue from Contracts with Customers and corresponding amendments, the revenue recognition process is now based on a five-step model to account for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. Topic 606 requires an entity to recognize
85
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We have identified all of our revenue streams and we have concluded that rental income from leasing arrangements represents a substantial portion of our revenue and, therefore, is specifically excluded from Topic 606 and will be governed under Topic 842 - Leases. The other revenue stream identified as impacting Topic 606 is concentrated in the recognition of real estate sales.
Investments in Real Estate
The majority of our investments in real estate are accounted for as asset acquisitions and the purchase price of tangible and intangible assets and liabilities are recorded based on their respective fair values. Tangible assets primarily consist of land and buildings and improvements. Additionally, the purchase price includes acquisition related expenses, above or below market leases, above or below market interests, in place leases, tenant relationships, above or below market debt assumed, interest rate swaps assumed and any contingent consideration recorded when the contingency is resolved. The determination of the fair value requires us to make certain estimates and assumptions.
With the assistance of independent valuation specialists, we record the purchase price of completed investments in real estate associated with tangible and intangible assets and liabilities based on their fair values. The tangible assets (land and building and improvements) are determined based upon the value of the property as if it were to be replaced or as if it were vacant using discounted cash flow models similar to those used by market participants. Factors considered by us include an estimate of carrying costs during the expected lease-up periods considering current market conditions and costs to execute similar leases. Additionally, the purchase price of the applicable completed acquisition property is inclusive of above or below market leases, above or below market leasehold interests, in place leases, tenant relationships, above or below market debt assumed, interest rate swaps assumed, any contingent consideration and acquisition related expenses.
The value of above or below market leases is determined based upon the present value (using a discount rate which reflects the risks associated with the acquired leases) of the difference between (i) the contractual amounts to be received pursuant to the lease over its remaining term and (ii) our estimate of the amounts that would be received using fair market rates over the remaining term of the lease including any bargain renewal periods. Under Topic 840, the amounts associated with above market leases are included in other intangibles, net in our accompanying consolidated balance sheets and amortized to rental income over the remaining lease term. The amounts allocated to below market leases are included in intangible liabilities, net in our accompanying consolidated balance sheets and amortized to rental income over the remaining lease term. Upon adoption of Topic 842 on January 1, 2019, the amounts associated with above market leases are included in right-of-use assets - operating leases, net in our accompanying consolidated balance sheets and amortized to rental income over the remaining lease term. The amounts allocated to below market leases are included in lease liabilities - operating leases in our accompanying consolidated balance sheets and amortized to rental income over the remaining lease term.
The value associated with above or below market leasehold interests is determined based upon the present value (using a discount rate which reflects the risks associated with the acquired leases) of the difference between: (i) the contractual amounts to be paid pursuant to the lease over its remaining term; and (ii) our estimate of the amounts that would be paid using fair market rates over the remaining term of the lease including any bargain renewal periods. Under Topic 840, the amounts recorded for above market leasehold interests are included in intangible liabilities, net in our accompanying consolidated balance sheets and amortized to rental expense over the remaining lease term. The amounts allocated to below market leasehold interests are included in other intangibles, net in our accompanying consolidated balance sheets and amortized to rental expense over the remaining lease term. Upon adoption of Topic 842 on January 1, 2019, the amounts recorded for above market leasehold interests are included in lease liabilities - operating leases in our accompanying consolidated balance sheets and amortized to rental expense over the remaining lease term. The amounts allocated to below market leasehold interests are included in right-of-use assets - operating leases, net in our accompanying consolidated balance sheets and amortized to rental expense over the remaining lease term.
The total amount of other intangible assets includes in place leases and tenant relationships based on our evaluation of the specific characteristics of each tenant’s lease and our overall relationship with that respective tenant. Characteristics considered by us in allocating these values include the nature and extent of the credit quality and expectations of lease renewals, among other factors. The amounts recorded for in place leases and tenant relationships are included in lease intangibles in our accompanying consolidated balance sheets and will be amortized to amortization expense over the remaining lease term.
The value recorded for above or below market debt is determined based upon the present value of the difference between the cash flow stream of the assumed mortgage and the cash flow stream of a market rate mortgage. The amounts recorded for above or below market debt are included in debt in our accompanying consolidated balance sheets and are amortized to interest expense over the remaining term of the assumed debt.
86
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
The value recorded for interest rate swaps is based upon a discounted cash flow analysis on the expected cash flows, taking into account interest rate curves and the remaining term. See derivative financial instruments below for further discussion.
The cost of operating properties includes the cost of land and buildings and related improvements. Expenditures that increase the service life of properties are capitalized and the cost of maintenance and repairs is charged to expense as incurred. The cost of buildings is depreciated on a straight-line basis over the estimated useful lives of the buildings up to 39 years and for tenant improvements, the shorter of the lease term or useful life, typically ranging from one to 10 years. Furniture, fixtures and equipment is depreciated over 5 years. Depreciation expense of buildings and improvements for the years ended December 31, 2021, 2020 and 2019, was $ 246.3 million, $ 235.8 million and $ 219.2 million, respectively.
Leases
As a lessor, we lease space in our MOBs primarily to medical enterprises for terms ranging from three to seven years in length. The assets underlying these leases consist of buildings and associated land which are included as real estate investments on our accompanying consolidated balance sheets. All of our leases for which we are the lessor are classified as operating leases under Topic 842.
Leases, for which we are the lessee, are classified as separate components on our accompanying consolidated balance sheets. Operating leases are included as right-of-use (“ROU”) assets - operating leases, net, with a corresponding lease liability. Financing lease assets are included in receivables and other assets, net, with a corresponding lease liability in security deposits, prepaid rent and other liabilities. A lease liability is recognized for our obligation related to the lease and an ROU asset represents our right to use the underlying asset over the lease term. Refer to Note 7 - Leases in the accompanying notes to the consolidated financial statements for more detail relating to our leases.
Through the duration of the COVID-19 pandemic, changes to our leases as a result of COVID-19 have been in two categories. Leases are categorized based upon the impact of the modification on its cash flows. One category is rent deferrals for which the guidance above was utilized, which provided relief from requiring a lease by lease analysis pursuant to Topic 842. These deferrals are generally for up to three months of rent with a payback period from three to twelve months once the deferral period has ended. Deferrals do not have an impact on cash flows over the lease term, rather, payments are made in different periods while the cash flows for the entirety of the lease term are the same. However, we have continued to recognize revenue and straight line revenue for amounts subject to deferral agreements in accordance with Topic 842. In 2020, which is the period that we believe constituted the majority of our COVID-19-related deferral request, we approved deferral plans totaling approximately $ 11.1 million, of which approximately $ 10.8 million have been repaid through December 31, 2021.
The second category is early renewals, where the Company renewed lease arrangements prior to their contractual expirations, providing concession at the commencement of the lease in exchange for additional term, on average approximately three years. This category is treated as a modification under Topic 842, with the existing balance of cumulative difference between rental income and payment amounts (existing straight line rent receivable) being recast over the new term, factoring in any changes attributable to the new lease arrangement and for which we performed a lease by lease analysis. Cash flows are impacted over the long term as customary free rent, at an average of three months in conjunction with these agreements, and is offset by substantively more term and/or increased rental rates. During the year ended December 31, 2021, the Company has entered into minimal new deferral arrangements or early renewal leases with substantive amounts of free rent or other forms of concession at the onset of the lease.
The Lease Modification Q&A had no material impact on our condensed consolidated financial statements as of and for the year ended December 31, 2021, however, its future impact to us is dependent upon the extent of lease concessions granted to tenants as a result of the COVID-19 pandemic in future periods and the elections made by us at the time of entering into any such concessions.
Development
We capitalize interest, direct and indirect project costs associated with the initial construction up to the time the property is substantially complete and ready for its intended use. In addition, we capitalize costs, including real estate taxes, insurance and utilities, that have been allocated to vacant space based on the square footage of the portion of the building not held available for immediate occupancy during the extended lease-up periods after construction of the building shell has been completed if costs are being incurred to ready the vacant space for its intended use. If costs and activities incurred to ready the vacant space cease, then cost capitalization is also discontinued until such activities are resumed. Once necessary work has been completed on a vacant space, project costs are no longer capitalized. We cease capitalization of all project costs on extended lease-up periods when significant activities have ceased, which does not exceed the shorter of a one-year period after the completion of the building shell or when the property attains 90% occupancy.
87
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
Real Estate Held for Sale
We consider properties held for sale once management commits to a plan to sell the property and has determined that the sale is probable and expected to occur within one year. Upon classification as held for sale, we record the property at the lower of its carrying amount or fair value, less costs to sell, and cease depreciation and amortization. The fair value is generally based on discounted cash flow analyses, which involve management’s best estimate of market participants’ holding period, market comparables, future occupancy levels, rental rates, capitalization rates, lease-up periods and capital requirements. As of December 31, 2021, we classified a single-tenant MOB located in the greater Atlanta, Georgia market as real estate held for sale on the accompanying consolidated balance sheets. As of December 31, 2020, the Company had no properties classified as held for sale. The following table represents the major classes of assets and liabilities, and the balance sheet classification as of December 31, 2021 (in thousands):
December 31, 2021
Land $ 2,401
Buildings and Improvements 27,408
Lease intangibles 4,769
34,578
Accumulated depreciation and amortization ( 8,148 )
Real estate assets held for sale, net 26,430
Receivables and other assets, net 640
Assets held for sale, net $ 27,070
Intangible liabilities, net $ 262
Liabilities of assets held for sale $ 262
Recoverability of Real Estate Investments
Real estate investments are evaluated for potential impairment whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Impairment indicators are assessed separately for each property and include, but are not limited to, significant decreases in real estate property net income, significant decreases in occupancy percentage, changes in management’s intent with respect to the properties and prevailing market conditions. Impairment losses are recorded when indicators of impairment are present and the carrying amount of the asset is greater than the sum of future undiscounted cash flows expected to be generated by that asset over the remaining expected holding period. We would recognize an impairment loss when the carrying amount is not recoverable to the extent the carrying amount exceeds the fair value of the property. The fair value is generally based on discounted cash flow analyses. In performing the analyses we consider executed sales agreements or management’s best estimate of market comparables, future occupancy levels, rental rates, capitalization rates, lease-up periods and capital requirements. For the year ended December 31, 2021, we recorded impairment charges of $ 22.9 million. During each of the years ended December 31, 2019 and 2020, we recorded no impairment charges.
Real Estate Notes Receivable
Real estate notes receivable consist of mezzanine and other real estate loans, which are generally collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner and/or corporate guarantees. Real estate notes receivable are intended to be held-to-maturity and are recorded at amortized cost, net of unamortized loan origination costs and fees and allowance for credit losses. During the year ended December 31, 2021, we originated three mezzanine loans with commitments totaling $ 60.1 million, at an annual interest rate of 8 %, maturing in 2024. Unpaid interest is capitalized, with principal and any unpaid interest due on the maturity date. As of December 31, 2021, mezzanine loans outstanding, including accrued interest totaled $ 54.8 million, net of unamortized loan fees. Additionally, during the year ended December 31, 2021, we originated a mortgage loan of $ 15.0 million, at an annual interest rate of 10 %, maturing in 2022. Interest on the mortgage loan was prefunded through an interest reserve and will be recognized as interest income through maturity, with principal and any unpaid interest due on the maturity date. As of December 31, 2021, real estate notes receivable, net totaled $ 69.1 million. During the year ended December 31, 2021, we recognized interest income of $ 2.8 million related to real estate notes receivable.
88
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
The following table summarizes real estate notes receivable as of December 31, 2021 (in thousands):
Stated Interest Rate Maximum Loan Commitment Outstanding Loan Amount
Origination Date Maturity Date December 31, 2021
Mezzanine Loans - Texas (1)
6/24/2021 6/24/2024 8 % $ 54,119 $ 49,319
Mezzanine Loan - North Carolina 12/22/2021 12/22/2024 8 % 6,000 6,000
Mortgage Loan - Texas 6/30/2021 7/1/2022 10 % 15,000 15,000
70,319
Accrued interest receivable 54
Unamortized fees and costs ( 526 )
Unearned revenue ( 733 )
$ 69,114
(1) Interest on these mezzanine loans is accrued and funded utilizing interest reserves, which is included in the maximum loan commitment, and such accrued interest is added to the note receivable balance.
Pursuant to Topic 326 - Financial Instruments - Credit Losses, we adopted a policy to evaluate current expected credit losses at the inception of loans qualifying for treatment under Topic 326. We utilize a probability of default method approach for estimating current expected credit losses and have determined that the current risk of credit loss is remote. Accordingly, we have recorded no reserve for credit loss as of December 31, 2021.
Unconsolidated Joint Ventures
We account for our investments in unconsolidated joint ventures using the equity method of accounting because we have the ability to exercise significant influence, but not control, over the financial and operational policy decisions of the investments. Using the equity method of accounting, the initial investment is recognized at cost and subsequently adjusted for our share of the net income and any distributions from the joint venture. As of December 31, 2021 and 2020, we had a 50 % interest in one such investment with a carrying value and maximum exposure to risk of $ 62.8 million and $ 64.4 million, respectively, which is recorded in investment in unconsolidated joint venture in the accompanying consolidated balance sheets. We record our share of net income in income from unconsolidated joint venture in the accompanying consolidated statements of operations. For the years ended December 31, 2021, 2020, and 2019, we recognized income from unconsolidated joint venture of $ 1.6 million, $ 1.6 million, and $ 1.9 million, respectively.
Derivative Financial Instruments
We are exposed to the effect of interest rate changes in the normal course of business. We seek to mitigate these risks by following established risk management policies and procedures which include the occasional use of derivatives. Our primary strategy in entering into derivative contracts is to add stability to interest expense and to manage our exposure to interest rate movements. We utilize derivative instruments, including interest rate swaps, to effectively convert a portion of our variable rate debt to fixed rate debt. We do not enter into derivative instruments for speculative purposes. To qualify for hedge accounting, derivative financial instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with our related assertions.
Derivatives are recognized as either assets or liabilities in our accompanying consolidated balance sheets and are measured at fair value. Changes in fair value of derivative financial instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are included as a component of interest expense in our accompanying consolidated statements of operations. As a result of our adoption of ASU 2017-12 as of January 1, 2018, the entire change in the fair value of derivatives designated and qualify as cash flow hedges are recorded in accumulated other comprehensive income (loss) in the accompanying consolidated balance sheets and are subsequently reclassified into earnings in the period in which the hedged forecasted transaction affects earnings. Since we solely use derivatives to hedge interest rate risk, amounts paid or received pursuant to our derivative agreements are included in interest expense on the consolidated statements of operations which then flows through to operating activities on the consolidated statements of cash flows. Additionally, as a result of the adoption of ASU 2017-12, we no longer disclose the ineffective portion of the change in fair value of our derivatives financial instruments designated as hedges.
The valuation of our derivative financial instruments is determined with the assistance of an independent valuation specialist using a proprietary model that utilizes widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative and observable inputs. The proprietary model reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves, foreign exchange rates and implied volatilities. The fair values of interest rate swaps are determined using the market standard
89
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
methodology of netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves.
We incorporate credit valuation adjustments to appropriately reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as collateral postings, thresholds, mutual puts and guarantees.
Fair Value Measurements
Fair value is a market-based measurement and is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Depending on the nature of the asset or liability, various techniques and assumptions can be used to estimate the fair value. Financial assets and liabilities are measured using inputs from three levels of the fair value hierarchy, as follows:
Level 1 — Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access at the measurement date. An active market is defined as a market in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active (markets with few transactions), inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data correlation or other means (market corroborated inputs).
Level 3 — Unobservable inputs, only used to the extent that observable inputs are not available, reflect our assumptions about the pricing of an asset or liability.
We use fair value measurements to record fair value of certain assets and to estimate fair value of financial instruments not recorded at fair value but required to be disclosed at fair value.
Receivables and Other Assets
Deferred financing costs include amounts paid to lenders and others to obtain financing and are amortized to interest expense on a straight-line basis over the term of the unsecured revolving credit facility which approximates the effective interest method. Deferred leasing costs are amounts incurred in executing a lease, both for external broker and marketing costs, plus a portion of internal leasing related costs. Deferred leasing costs are amortized on a straight-line basis method over the term of the applicable lease. Deferred leasing costs are included in operating activities in our accompanying consolidated statements of cash flows.
Share-Based Compensation
We calculate the fair value of share-based awards on the date of grant. Restricted common stock is valued based on the closing price of our common stock on the NYSE. We amortize the share-based compensation expense over the period that the awards are expected to vest, net of estimated forfeitures. See Note 11 - Stockholders’ Equity and Partners’ Capital for further discussion.
Non-controlling Interests
HTA’s net income attributable to non-controlling interests in the accompanying consolidated statements of operations relate to non-controlling interest reflected within equity. OP Units, including LTIP awards, are accounted for as partners’ capital in HTALP’s accompanying consolidated balance sheets and as non-controlling interest reflected within equity in HTA’s accompanying consolidated balance sheets.
Income Taxes
HTA believes that it has qualified to be taxed as a REIT under the provisions of the Code, beginning with the taxable year ending December 31, 2007 and it intends to continue to qualify to be taxed as a REIT. To continue to qualify as a REIT for federal income tax purposes, HTA must meet certain organizational and operational requirements, including a requirement to pay dividend distributions to its stockholders of at least 90% of its annual taxable income. As a REIT, HTA is generally not subject to federal income tax on net income that it distributes to its stockholders, but it may be subject to certain state or local taxes and fees.
90
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
If HTA fails to qualify as a REIT in any taxable year, it will then be subject to U.S. federal income taxes on our taxable income and will not be permitted to qualify for treatment as a REIT for U.S. federal income tax purposes for four years following the year during which qualification is lost unless the IRS grants it relief under certain statutory provisions. Such an event could have a material adverse effect on its business, financial condition, results of operations and net cash available for dividend distributions to its stockholders.
HTA conducts substantially all of its operations through HTALP. As a partnership, HTALP generally is not liable for federal income taxes. The income and loss from the operations of HTALP is included in the tax returns of its partners, including HTA, who are responsible for reporting their allocable share of the partnership income and loss. Accordingly, no provision for income taxes has been made on the accompanying consolidated financial statements.
We do not have any liability for uncertain tax positions that we believe should be recognized in our accompanying consolidated financial statements. The tax basis exceeded the carrying amount of the net real estate assets reported in our accompanying consolidated balance sheet by approximately $ 766.9 million as of December 31, 2021, primarily due to the differences in depreciation and amortization.
Concentration of Credit Risk
We maintain the majority of our cash and cash equivalents at major financial institutions in the U.S. and deposits with these financial institutions may exceed the amount of insurance provided on such deposits; however, we regularly monitor the financial stability of these financial institutions and believe we are not currently exposed to any significant default risk with respect to these deposits. As of December 31, 2021, we had cash balances at financial institutions of $ 62.5 million in excess of Federal Deposit Insurance Corporation insured limits.
Segment Disclosure
We have determined that we have one reportable segment, with activities related to investing in healthcare real estate assets. Our investments in healthcare real estate assets are geographically diversified and our chief operating decision maker evaluates operating performance on an individual asset level. As each of our assets has similar economic characteristics, long-term financial performance, tenants, and products and services, our assets have been aggregated into one reportable segment.
Related Party Aircraft Use
HTA owns an airplane that is used for business purposes. The Chief Executive Officer of the Company is permitted to use the aircraft for personal travel and, pursuant to a policy adopted by HTA relating to such personal use, the Company is reimbursed by the executive for the incremental costs of using the aircraft for personal travel.
Recently Issued or Adopted Accounting Pronouncements
Recently Adopted Accounting Pronouncements
S-X Rule 13-01
In March 2020, the SEC adopted amendments to Rule 3-10 of Regulation S-X and created Rule 13-01 to simplify disclosure requirements related to certain registered securities. The rule became effective on January 4, 2021, at which time we adopted S-X Rule 13-01. The adoption did not have a material effect on our financial statements and related footnotes.
Recently Issued Accounting Pronouncements
ASU 2021-01, Reference Rate Reform (Topic 848)
In January 2021, the FASB issued ASU 2021-01, which amends the scope of ASU 2020-04. The amendments of ASU 2021-01 clarify that certain optional expedients and exceptions to Topic 848 for contract modification and hedge accounting apply to derivatives that are affected by the discounting transition. For information related to the Company's current cash flow hedges, refer to Note 9 - Derivative Financial Instruments and Hedging Activities. The amendments are elective and effective immediately for contract modifications made through December 31, 2022. The Company is evaluating how the transition away from LIBOR will effect the Company and if the guidance with respect to this standard will be adopted, however, if adopted, we do not expect that this ASU will have a material impact on our financial statements.
ASU 2021-05, Leases (Topic 842): Lessors - Certain Leases with Variable Lease Payments
In July 2021, the FASB issued ASU 2021-05, which amends the lease classification requirements for lessors when classifying and accounting for a lease with variable lease payments that do not depend on a reference index or a rate. The update provides criteria, that if met, the lease would be classified and accounted for as an operating lease. The update is effective for reporting periods beginning after December 15, 2021, with early adoption permitted. At this time, the Company does not expect that the adoption of this standard will have a material impact on our financial statements.
91
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
3. Investments in Real Estate
For the year ended December 31, 2021, our investments had an aggregate purchase price of $ 308.8 million. As part of these investments, we incurred approximately $ 2.1 million of capitalized costs. The allocations for these investments, in which we own a controlling financial interest, are set forth below in the aggregate for the years ended December 31, 2021, 2020 and 2019, respectively (in thousands):
Year Ended December 31,
2021 2020 2019
Land $ 44,905 $ 15,242 $ 108,709
Building and improvements 233,219 156,486 396,660
In place leases 23,056 17,948 51,629
Below market leases ( 4,592 ) ( 1,132 ) ( 5,187 )
Above market leases 3,283 1,215 3,487
ROU assets 300 1,527 —
Net assets acquired 300,171 191,286 555,298
Other, net (1)
8,593 432 5,158
Aggregate purchase price $ 308,764 $ 191,718 $ 560,456
(1) Other, net, consisted primarily of tenant improvements and capital expenditures received as credits at the time of acquisition.
Subsequent to December 31, 2021, we completed an investment with a purchase price of $ 19.0 million. The
purchase price of this investment was subject to certain post-closing adjustments. Due to the recent timing of the
acquisition of this investment, we have not completed our purchase price allocation with respect to this investment and,
therefore, cannot provide disclosures at this time similar to those contained above in Note 3 - Investments in Real Estate to our
consolidated financial statements.
The acquired intangible assets and liabilities referenced above had weighted average lives of the following terms for the years ended December 31, 2021, 2020 and 2019, respectively (in years):
Year Ended December 31,
2021 2020 2019
Acquired intangible assets 6.5 10.2 5.7
Acquired intangible liabilities 8.0 7.1 7.0
4. Dispositions and Impairment
Dispositions
During the year ended December 31, 2021, we completed the disposition of fifteen MOBs, located in Tennessee, Virginia, Minnesota and Ohio for an aggregate gross sales price of $ 88.3 million, representing approximately 599,000 square feet of GLA, in addition to the sale of our interest in a land parcel in Connecticut on which the ground lessee exercised its purchase option for a gross sales price of $ 1.8 million, resulting in a net gain to us of approximately $ 39.2 million.
During the year ended December 31, 2020, we completed the disposition of one MOB, located in Kansas City for an aggregate gross sales price of $ 24.3 million, representing approximately 69,000 square feet of GLA, and generating net gains of approximately $ 7.6 million. Additionally, during the year ended December 31, 2020, we sold part of our interest in undeveloped land in Miami, Florida for a gross sales price of $ 7.6 million which resulted in a net gain of approximately $ 2.0 million.
During the year ended December 31, 2019, we completed the disposition of four MOBs, located in South Carolina and New Mexico for an aggregate gross sales price of $ 4.9 million, representing approximately 51,000 square feet of GLA, and generating net losses of $ 0.2 million.
Subsequent to December 31, 2021, we closed a tenant purchase option transaction on a property located in Georgia for a gross sales price of $ 26.8 million. This property is properly classified as held for sale as of December 31, 2021. For more details, see Note 2 - Summary of Significant Accounting Policies in the “Real Estate Held for Sale” section.
92
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
Impairment
During the year ended December 31, 2021, we recorded impairment charges of $ 22.9 million on four properties, one of which was sold as of December 31, 2021. The other three properties are located in Georgia, Texas and New Mexico. During each of the years ended December 31, 2020 and 2019, we recorded no impairment charges. For more details, see Note 2 - Summary of Significant Accounting Policies in the “Recoverability of Real Estate Investments” section.
5. Intangible Assets and Liabilities
Intangible assets and liabilities consisted of the following as of December 31, 2021 and 2020, respectively (in thousands, except weighted average remaining amortization terms):
December 31, 2021 December 31, 2020
Balance Weighted Average Remaining
Amortization in Years Balance Weighted Average Remaining
Amortization in Years
Assets:
In place leases
$ 349,863 9.3 $ 483,779 9.7
Tenant relationships
54,851 10.8 144,842 10.0
Above market leases
21,537 6.9 37,876 5.8
426,251 666,497
Accumulated amortization ( 213,801 ) ( 427,937 )
Total $ 212,450 9.3 $ 238,560 9.6
Liabilities:
Below market leases $ 55,073 14.3 $ 61,896 14.6
Accumulated amortization ( 23,742 ) ( 29,357 )
Total $ 31,331 14.3 $ 32,539 14.6
The following is a summary of the net intangible amortization for the years ended December 31, 2021, 2020 and 2019, respectively (in thousands):
Year Ended December 31,
2021 2020 2019
Amortization recorded against rental income related to above and (below) market leases
$ ( 2,638 ) $ ( 4,056 ) $ ( 4,422 )
Amortization expense related to in place leases and tenant relationships
45,447 55,138 60,363
As of December 31, 2021, the expected future amortization of intangible assets and liabilities is as follows (in thousands):
Year Assets Liabilities
2022 $ 40,676 $ 5,254
2023 33,161 4,408
2024 27,345 3,798
2025 23,136 3,161
2026 19,437 2,686
Thereafter 68,695 12,024
Total $ 212,450 $ 31,331
93
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
6. Receivables and Other Assets
Receivables and other assets consisted of the following as of December 31, 2021 and 2020, respectively (in thousands):
December 31,
2021 2020
Tenant receivables, net
$ 10,477 $ 17,717
Other receivables, net
6,098 6,243
Deferred financing costs, net
7,055 2,586
Deferred leasing costs, net
45,008 43,234
Straight-line rent receivables, net 142,604 128,070
Prepaid expenses, deposits, equipment and other, net 38,301 46,114
Real estate notes receivable, net 69,114 —
Finance ROU asset, net 16,284 7,764
Total $ 334,941 $ 251,728
The following is a summary of the amortization of deferred leasing costs and financing costs for the years ended December 31, 2021, 2020 and 2019, respectively (in thousands):
Year Ended December 31, 2021
2021 2020 2019
Amortization expense related to deferred leasing costs
$ 8,831 $ 8,755 $ 7,976
Interest expense related to amortization of deferred financing costs 1,753 1,724 1,724
As of December 31, 2021, the expected future amortization of deferred leasing costs and financing costs is as follows (in thousands):
Year Amount
2022 $ 10,287
2023 9,263
2024 8,203
2025 6,939
2026 4,560
Thereafter 12,811
Total $ 52,063
7. Leases
The majority of our lease expenses are derived from our ground leases and a few corporate leases, which are primarily for office space . We recognize lease expense for these leases on a straight-line basis over the lease term. Many of our leases contain renewal options that can extend the lease term from one to ten years , or in certain cases, longer durations. The exercise of lease renewal options is at our sole discretion. Certain of our ground leases have the option to purchase the land at the end of the initial term. Our leases have one of the following payment options: (i) fixed payment throughout the term; (ii) fixed payments with periodic escalations; (iii) variable lease payments based on the Consumer Price Index (“CPI”) or another similar index; and (iv) a combination of the aforementioned. Our leases do not contain any material residual value guarantees or material restrictive covenants other than certain prohibitions as to the nature of business that can be conducted within the buildings which we own in order to limit activities that may be deemed competitive in nature to the ground lessor’s activities. As of December 31, 2021, we have no new ground leases or corporate leases that have not yet commenced.
During the year ended December 31, 2021, we assumed five new ground leases as part of building acquisitions made during the year. The new ground leases were analyzed and three were classified as finance leases and two were classified as operating leases. Additionally, during the year ended December 31, 2021, nine of our in-place operating ground leases were removed as a result of property dispositions. For more details on the dispositions, refer to Note 4 - Dispositions and Impairment.
94
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
Lessee - Lease Term and Discount Rates
The following is the weighted average remaining lease term and the weighted average discount rate for our operating and finance leases as of December 31, 2021 (weighted average remaining lease term in years):
December 31, 2021
Operating leases:
Weighted-average remaining lease term
46.5
Weighted-average discount rate
5.3 %
Finance leases:
Weighted-average remaining lease term
48.1
Weighted-average discount rate
3.8 %
Lessee - Maturity of Lease Liabilities
We have ground leases and other operating leases with landlords that generally require fixed annual rental payments and may also include escalation clauses and renewal options. These leases generally have terms up to 99 years, excluding extension options. The following table summarizes the future minimum lease obligations of our operating and finance leases as of December 31, 2021 under Topic 842 (in thousands):
Year Operating leases Finance leases
2022 $ 10,568 $ 630
2023 10,758 635
2024 10,370 640
2025 9,857 645
2026 9,869 656
Thereafter 599,954 37,524
Total undiscounted lease payments $ 651,376 $ 40,730
Less: Interest ( 455,090 ) ( 23,826 )
Present value of lease liabilities $ 196,286 $ 16,904
Lessor - Lease Revenues and Maturity of Future Minimum Rents
We have operating leases with tenants that expire at various dates through 2043 which generally include fixed increases or adjustment based on the consumer price index. Leases also provide for additional rents based on certain operating expenses.
For the years ended December 31, 2021, 2020 and 2019, we recognized $ 761.7 million, $ 732.5 million and $ 686.2 million, respectively, of rental and other lease-related income related to our operating leases, of which $ 175.7 million, $ 169.1 million and $ 154.3 million, respectively, were variable lease payments.
The following table summarizes the future minimum rent contractually due under operating leases, excluding tenant reimbursements of certain costs, as of December 31, 2021 under Topic 842 (in thousands):
Year Amount
2022 $ 569,363
2023 524,166
2024 466,821
2025 407,880
2026 360,766
Thereafter 1,322,375
Total $ 3,651,371
95
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
8. Debt
Debt consisted of the following as of December 31, 2021 and 2020, respectively (in thousands):
December 31,
2021 2020
Unsecured revolving credit facility $ — $ —
Unsecured term loans 500,000 500,000
Unsecured senior notes 2,550,000 2,550,000
Fixed rate mortgages — —
3,050,000 3,050,000
Deferred financing costs, net ( 17,975 ) ( 19,157 )
Net premium (discount) ( 3,903 ) ( 3,844 )
Total $ 3,028,122 $ 3,026,999
Unsecured Credit Agreement
Unsecured Revolving Credit Facility due 2025
On October 6, 2021, we entered into a third amended and restated revolving credit and term loan agreement (the “Credit Agreement”), which includes an unsecured revolving credit facility in an aggregate maximum principal amount of $ 1.0 billion (the “Revolver”) and a term loan facility in an aggregate maximum principal amount of $ 300.0 million (the “Term Loan”). The Credit Agreement extended the maturities of the unsecured revolving credit facility and the unsecured term loan to October 31, 2025. The maximum principal amount of the Unsecured Credit Agreement may be increased by up to $ 750.0 million, subject to certain conditions, for a total principal amount of $ 2.05 billion. Borrowings under the Revolver bears interest at a per annum rate equal to LIBOR plus a margin ranging from 0.725 % to 1.40 % based on our credit rating. We are also required to pay a facility fee on the aggregate commitments under the Revolver at a per annum rate ranging from 0.125 % to 0.30 % based on our credit rating. We incurred financing costs of $ 6.2 million in relation to the credit facility, which are being amortized through the maturity date. As of December 31, 2021, we had no outstanding balance under this unsecured revolving credit facility. The margin associated with our borrowings was 0.85 % per annum and the facility fee was 0.20 % per annum.
Accrued interest under the Credit Agreement is payable quarterly and at maturity. The Credit Agreement includes customary LIBOR replacement terms and contains a sustainability-linked feature, which allows for a reduction in pricing upon our realization of certain sustainability ratings. The other terms of the Credit Agreement prior to the amendment thereof remain substantially unchanged.
$ 300.0 Million Unsecured Term Loan due 2025
Under the Unsecured Credit Agreement as noted above, we have a $ 300.0 million unsecured term loan, guaranteed by HTA, with a maturity date of October 31, 2025. Borrowings under this unsecured term loan bear interest at a per annum rate equal to LIBOR, plus a margin ranging from 0.80 % to 1.60 % per annum based on our credit rating. The margin associated with our borrowings as of December 31, 2021 was 0.95 % per annum. We incurred financing costs of $ 1.8 million in relation to the unsecured term loan, which are being amortized through the maturity date. We have interest rate swaps hedging the floating interest rate, which resulted in a fixed rate of 2.37 % per annum, based on our current credit rating. The current hedging arrangement matures on February 1, 2023. As of December 31, 2021, we had $ 300.0 million under this unsecured term loan outstanding.
$ 200.0 Million Unsecured Term Loan due 2024
In 2018, HTALP entered into a modification of our $ 200.0 million unsecured term loan previously due in 2023. The modification decreased pricing at our current credit rating by 65 basis points and extended the maturity date to January 15, 2024. The other material terms of the unsecured term loan prior to the modification remained substantially unchanged. Borrowings under the unsecured term loan accrue interest at a rate equal to LIBOR, plus a margin ranging from 0.75 % to 1.65 % per annum based on our credit rating. The margin associated with our borrowings as of December 31, 2021 was 1.00 % per annum. HTALP had interest rate swaps on the balance, which resulted in a fixed interest rate at 2.32 % per annum. As of December 31, 2021, HTALP had $ 200.0 million under this unsecured term loan outstanding.
96
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
$ 600.0 Million Unsecured Senior Notes due 2026
In September 2019, in connection with the $ 650.0 million unsecured senior notes due 2030 referenced below, HTALP issued $ 250.0 million as additional unsecured senior notes to the $ 350.0 million aggregate principal of senior notes issued on July 12, 2016, all of which are guaranteed by HTA. These unsecured senior notes are registered under the Securities Act, bear interest at 3.50 % per annum and are payable semi-annually. Additionally, these unsecured senior notes were offered at 103.66 % and 99.72 %, respectively, of the principal amount thereof, with an effective yield to maturity of 2.89 % and 3.53 %, respectively, per annum. As of December 31, 2021, HTALP had $ 600.0 million of these unsecured senior notes outstanding that mature on August 1, 2026.
$ 500.0 Million Unsecured Senior Notes due 2027
In 2017, HTALP issued $ 500.0 million of unsecured senior notes that are guaranteed by HTA. These unsecured senior notes are registered under the Securities Act, bear interest at 3.75 % per annum and are payable semi-annually. Additionally, these unsecured senior notes were offered at 99.49 % of the principal amount thereof, with an effective yield to maturity of 3.81 % per annum. As of December 31, 2021, HTALP had $ 500.0 million of these unsecured senior notes outstanding that mature on July 1, 2027.
$ 650.0 Million Unsecured Senior Notes due 2030
In September 2019, in connection with the $ 250.0 million additional unsecured senior notes due 2026 referenced above, HTALP issued $ 650.0 million of unsecured senior notes that are guaranteed by HTA. These unsecured senior notes are registered under the Securities Act, bear interest at 3.10 % per annum and are payable semi-annually. Additionally, these unsecured senior notes were offered at 99.66 % of the principal amount thereof, with an effective yield to maturity of 3.14 % per annum. As of December 31, 2021, HTALP had $ 650.0 million of these unsecured senior notes outstanding that mature on February 15, 2030. Proceeds from the issuance of $ 900.0 million of these notes were used, in part, to redeem a total of $ 700.0 million of unsecured senior notes. During the year ended December 31, 2019, the make-whole fees required per the terms of the indenture agreements upon our calling the notes totaling $ 18.3 million was recorded in loss on extinguishment of debt in the accompanying consolidated statements of operations.
$ 800.0 Million Unsecured Senior Notes due 2031
In September 2020, HTALP issued $ 800.0 million of unsecured senior notes that are guaranteed by HTA. These unsecured senior notes are registered under the Securities Act, bear interest at 2.00 % per annum and are payable semi-annually. Additionally, these unsecured notes were offered at 99.20 % of the principal amount thereof, with an effective yield to maturity of 2.09 % per annum. We incurred financing costs of $ 6.8 million in relation to this transaction, which are being amortized through the maturity date. As of December 31, 2021, HTALP had $ 800.0 million of these unsecured senior notes outstanding that mature on March 15, 2031. Proceeds from the issuance of these unsecured notes were used, in part, to redeem $ 300.0 million of unsecured senior notes. During the year ended December 31, 2020, the make-whole fee that was required per the terms of the indenture agreement upon our calling the notes of $ 24.7 million was recorded in loss on extinguishment of debt in the accompanying consolidated statements of operations.
Future Debt Maturities
The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of December 31, 2021 (in thousands):
Year Amount
2022 $ —
2023 —
2024 200,000
2025 300,000
2026 600,000
Thereafter 1,950,000
Total $ 3,050,000
97
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
Deferred Financing Costs
As of December 31, 2021, the expected future amortization of our deferred financing costs is as follows (in thousands):
Year Amount
2022 $ 3,106
2023 3,106
2024 2,724
2025 2,603
2026 1,839
Thereafter 4,597
Total $ 17,975
Debt Covenants
We are required by the terms of our applicable loan agreements to meet various affirmative and negative covenants that we believe are customary for these types of facilities, such as limitations on the incurrence of debt by us and our subsidiaries that own unencumbered assets, limitations on the nature of HTALP’s business, and limitations on distributions by HTALP and its subsidiaries that own unencumbered assets. Our loan agreements also impose various financial covenants on us, such as a maximum ratio of total indebtedness to total asset value, a minimum ratio of EBITDA to fixed charges, a minimum tangible net worth covenant, a maximum ratio of unsecured indebtedness to unencumbered asset value, rent coverage ratios and a minimum ratio of unencumbered NOI to unsecured interest expense. As of December 31, 2021, we believe that we were in compliance with all such financial covenants and reporting requirements. In addition, certain of our loan agreements include events of default provisions that we believe are customary for these types of facilities, including restricting us from making dividend distributions to our stockholders in the event we are in default thereunder, except to the extent necessary for us to maintain our REIT status.
9. Derivative Financial Instruments and Hedging Activities
Risk Management Objective of Using Derivative Financial Instruments
We may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with our borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with our operating and financial structure as well as to hedge specific anticipated transactions. We do not intend to utilize derivatives for speculative or other purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, we only enter into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which we and our affiliates may also have other financial relationships. We do not anticipate that any of the counterparties will fail to meet their obligations. We record counterparty credit risk valuation adjustments on interest rate swap derivative assets in order to properly reflect the credit quality of the counterparty. In addition, our fair value of interest rate swap derivative liabilities is adjusted to reflect the impact of our credit quality.
Cash Flow Hedges of Interest Rate Risk
Our objectives in using interest rate derivatives are to add stability to interest expense and to manage our exposure to interest rate movements. To accomplish this objective, we primarily use interest rate swaps and treasury locks as part of our interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable rate amounts from a counterparty in exchange for us making fixed rate payments over the life of the agreements without exchange of the underlying notional amount. A treasury lock is a synthetic forward sale of a U.S. treasury note, which is settled in cash based upon the difference between an agreed upon treasury rate and the prevailing treasury rate at settlement. Such treasury locks are entered into to effectively fix the treasury component of an upcoming debt issuance.
Amounts reported in accumulated other comprehensive income (loss) in the accompanying consolidated balance sheets related to derivatives will be reclassified to interest expense as interest payments are made on our variable rate debt. During the next twelve months, we estimate that an additional $ 4.9 million will be reclassified from other comprehensive income (loss) in the accompanying consolidated balance sheets as an increase to interest related to derivative financial instruments in the accompanying consolidated statements of operations.
98
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
As of December 31, 2021, we had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk (in thousands, except number of instruments):
Cash Flow Hedges December 31, 2021
Number of instruments 7
Notional amount $ 500,000
The table below presents the fair value of our derivative financial instruments designated as a hedge as well as our classification in the accompanying consolidated balance sheets as of December 31, 2021 and 2020, respectively (in thousands). We had no offsetting derivatives as of December 31, 2021 .
Asset Derivatives Liability Derivatives
Fair Value at: Fair Value at:
Derivatives Designated as Hedging Instruments: Balance Sheet
Location December 31, 2021 December 31, 2020 Balance Sheet
Location December 31, 2021 December 31, 2020
Interest rate swaps Receivables and other assets $ — $ — Derivative financial instruments $ 5,069 $ 14,957
The table below presents the gain or loss recognized on our derivative financial instruments designated as hedges as well as our classification in the accompanying consolidated statements of operations for the years ended December 31, 2021, 2020 and 2019, respectively (in thousands).
Year Ended December 31,
Effect of Derivative Instruments Operations and Comprehensive (Loss) Income 2021 2020 2019
(Loss) gain recognized in OCI Change in unrealized losses on cash flow hedges $ 3,393 $ ( 25,773 ) $ 5,910
(Loss) gain reclassified from accumulated OCI into income Interest expense ( 6,721 ) ( 3,897 ) 1,594
Non-Designated Hedges
Derivatives not designated as hedges are not speculative and are used to manage our exposure to interest rate movements and other identified risks, but do not meet the strict hedge accounting requirements of ASC 815 - Derivatives and Hedging. Changes in the fair value of derivatives not designated in hedging relationships are recorded directly in earnings. Changes in the fair value of derivatives not designated in hedging relationships are recorded directly to gain or loss on change in fair value of derivative financial instruments in the accompanying consolidated statements of operations. There were no non-designated hedges as of December 31, 2021, 2020 and 2019, respectively.
Credit Risk Related Contingent Features
We have agreements with each of our derivative counterparties that contain a provision that if we default on any of our indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender, then we could also be declared in default on our derivative obligations.
We also have agreements with each of our derivative counterparties that incorporate provisions from our indebtedness with a lender affiliate of the derivative counterparty requiring it to maintain certain minimum financial covenant ratios on our indebtedness. Failure to comply with the covenant provisions would result in us being in default on any derivative instrument obligations covered by these agreements.
As of December 31, 2021, the fair value of derivatives in a net liability position, including accrued interest, but excluding any adjustment for nonperformance risk related to these agreements, was $ 5.2 million. As of December 31, 2021, we have not posted any collateral related to these agreements and we were not in breach of any of the provisions of these agreements. If we had breached any of the provisions of these agreements, we could have been required to settle our obligations under these agreements.
10. Commitments and Contingencies
Litigation
We engage in litigation from time to time with various parties as a routine part of our business, including tenant defaults and threatened or asserted labor matters. However, we are not presently subject to any material litigation nor, to our knowledge, is any material litigation threatened against us, which if determined unfavorably to us, would have a material effect on our consolidated financial position, results of operations or cash flows.
99
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
Environmental Matters
We follow the policy of monitoring our properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at our properties, we are not currently aware of any environmental liability with respect to our properties that would have a material effect on our consolidated financial position, results of operations or cash flows. Further, we are not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability at our properties that we believe would require additional disclosure or the recording of a loss contingency.
Other
Our other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business. In our opinion, these matters are not expected to have a material effect on our consolidated financial position, results of operations or cash flows.
11. Stockholders’ Equity and Partners’ Capital
HTALP’s operating partnership agreement provides that it will distribute cash flow from operations and net sale proceeds to its partners in accordance with their overall ownership interests at such times and in such amounts as the general partner determines. Dividend distributions are made such that a holder of one OP Unit in HTALP will receive distributions from HTALP in an amount equal to the dividend distributions paid to the holder of one share of our common stock. In addition, for each share of common stock issued or redeemed by us, HTALP issues or redeems a corresponding number of OP Units.
Common Stock Offerings
In March 2021, we entered into equity distribution agreements with various sales agents with respect to our at-the-market ("ATM") offering program of common stock with an aggregate sales amount of up to $ 750.0 million, which replaced our prior ATM offering program that expired in February 2021. As of December 31, 2021, $ 750.0 million remained available for issuance by us under our current ATM.
During the year ended December 31, 2021, we issued approximately 9.4 million shares of our common stock under our ATM for net proceeds of approximately $ 251.3 million, adjusted for costs to borrow equating to a net price to us of $ 26.68 per share of common stock. Refer to Note 13 - Per Share Data of HTA to these consolidated financial statements for a more detailed discussion related to our forward equity agreements.
Stock Repurchase Plan
In September 2020, our Board of Directors approved a stock repurchase plan authorizing us to purchase up to $ 300.0 million of our common stock from time to time prior to the expiration thereof on September 22, 2023. As of December 31, 2021, the remaining amount of common stock available for repurchase under the stock repurchase plan was $ 300.0 million.
Common Stock Dividends
See our accompanying consolidated statements of equity and changes in partners’ capital for the dividends declared during the years ended December 31, 2021, 2020 and 2019. As of December 31, 2021 and 2020, declared but unpaid dividends totaling $ 75.7 million and $ 71.4 million, respectively, were included in accounts payable and accrued liabilities. On February 28, 2022, our Board of Directors announced a quarterly cash dividend of $ 0.325 per share of common stock and per OP Unit to be paid on April 11, 2022 to stockholders and unitholders of record on April 4, 2022.
Incentive Plan
Our Incentive Plan permits the grant of incentive awards to our employees, officers, non-employee directors and consultants as selected by our Board of Directors. This Plan authorizes us to grant awards in any of the following forms: options; stock appreciation rights; restricted stock; restricted or deferred stock units; performance awards; dividend equivalents; other stock-based awards, including units in HTALP; and cash-based awards. Subject to adjustment as provided in the Plan, the aggregate number of awards reserved and available for issuance under the Plan is 10,000,000 shares. As of December 31, 2021, there were 9,804,333 awards available for grant under the Plan.
Restricted Common Stock
The weighted average fair value of restricted common stock granted during the years ended December 31, 2021, 2020 and 2019, were $ 28.14 , $ 29.83 and $ 26.08 , respectively. The fair value of restricted common stock for which the restriction lapsed during the years ended December 31, 2021, 2020 and 2019 were $ 8.2 million, $ 12.6 million and $ 8.9 million, respectively.
100
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
We recognized compensation expense, equal to the fair market value of HTA’s stock on the grant date, over the service period which is generally three to four years . For the years ended December 31, 2021, 2020 and 2019, we recognized compensation expense of $ 7.3 million, $ 8.9 million and $ 10.1 million respectively. Substantially all compensation expense was recorded in general and administrative expenses in the accompanying consolidated statements of operations.
As of December 31, 2021, we had $ 6.9 million of unrecognized compensation expense, net of estimated forfeitures, which we will recognize over a remaining weighted average period of 1.6 years.
The following is a summary of our restricted common stock activity as of December 31, 2021 and 2020, respectively:
December 31, 2021 December 31, 2020
Restricted Common Stock Weighted
Average Grant
Date Fair Value Restricted Common Stock Weighted
Average Grant
Date Fair Value
Beginning balance 436,399 $ 28.27 600,987 $ 28.04
Granted 552,989 28.14 273,503 29.83
Vested ( 297,555 ) 27.47 ( 426,693 ) 28.93
Forfeited ( 161,971 ) 27.47 ( 11,398 ) 28.88
Ending balance 529,862 $ 28.83 436,399 $ 28.27
12. Fair Value of Financial Instruments
Financial Instruments Reported at Fair Value - Recurring
The table below presents the carrying amounts and fair values of our financial instruments on a recurring basis as of December 31, 2021 and 2020 (in thousands):
December 31, 2021 December 31, 2020
Carrying Amount Fair Value Carrying Amount Fair Value
Level 2 - Assets:
Real estate notes receivable, net $ 69,114 $ 68,476 $ — $ —
Level 2 - Liabilities:
Derivative financial instruments $ 5,069 $ 5,069 $ 14,957 $ 14,957
Debt 3,028,122 3,117,602 3,026,999 3,258,573
The carrying amounts of cash and cash equivalents, tenant and other receivables, restricted cash, accounts payable, and accrued liabilities approximate fair value. There have been no transfers of assets or liabilities between levels. We will record any such transfers at the end of the reporting period in which a change of event occurs that results in a transfer. Although we have determined that the majority of the inputs used to value our cash flow hedges fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. However, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our cash flow hedge positions and have determined that the credit valuation adjustments are not significant to their overall valuation. As a result, we have determined that our cash flow hedge valuations in their entirety are classified in Level 2 of the fair value hierarchy. For further discussion of the assumptions considered, refer to Note 2 - Summary of Significant Accounting Policies.
101
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
Financial Instruments Reported at Fair Value - Non-Recurring
We also have assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This generally includes assets subject to impairment. We estimate fair value relating to impairment assessments based upon discounted cash flow and direct capitalization models that include all projected cash inflows and outflows over a specific holding period, or the contractual sales price, if applicable. Such projected cash flows are comprised of contractual rental revenues and forecasted rental revenues and expenses based on market conditions and expectations for growth. Capitalization rates and discount rates utilized in these models are based on a reasonable range of current market rates for each property analyzed. Based on these inputs, we determined that our valuation of properties using a discounted cash flow or a direct capitalization model were classified within Level 3 of the fair value hierarchy. For assets for which the estimated fair value was based on contractual sales prices, we determined that our valuation was classified within Level 2 of the fair value hierarchy. As of December 31, 2021, the estimated fair value for one real estate investment within Level 2 of the fair value hierarchy was based on the purchase price set forth in an executed purchase option, less estimated closing costs. The estimated fair value for two real estate investments within Level 3 of the fair value hierarchy was based on income capitalization models utilizing a capitalization rate of 7.00 %.
The table below presents our assets measured at fair value on a non-recurring basis as of December 31, 2021 and 2020 (in thousands):
December 31, 2021 December 31, 2020
Fair Value Fair Value
Level 2 - Assets:
Real estate investment $ 26,768 $ —
Level 3 - Assets:
Real estate investments $ 4,970 $ —
13. Per Share Data of HTA
During the year ended December 31, 2021, we issued approximately 9.4 million shares of our common stock under our ATM for net proceeds of approximately $ 251.3 million, adjusted for costs to borrow equating to a net price to us of $ 26.68 per share of common stock.
To account for the forward equity agreement, we considered the accounting guidance governing financial instruments and derivatives and concluded that our forward equity agreement was not a liability as it did not embody obligations to repurchase our shares of common stock nor did it embody obligations to issue a variable number of shares for which the monetary value was predominately fixed, varying with something other than the fair value of the shares, or varying inversely in relation to our shares. We also evaluated whether the agreement met the derivatives and hedging guidance scope exception to be accounted for as an equity instrument and concluded that the agreement can be classified as an equity contract based on the following assessment: (i) the agreement did not exercise contingencies were based on observable markets or indices besides those related to the market for our own stock price and operations; and (ii) none of the settlement provisions precluded the agreement from being indexed to our own common stock.
In addition, we considered the potential dilution resulting from the forward equity agreement(s) on our earnings per common share calculations. We used the treasury method to determine the dilution resulting from the forward equity agreement(s) during the period of time prior to settlement. The number of weighted-average shares outstanding used in the computation of earnings per common share for the year ended December 31, 2021, included the effect from the assumed issuance of 9.4 million shares issued during 2019 and 2020, respectively, pursuant to the settlement(s) of the forward equity agreement(s) at the contractual price(s), less the assumed repurchase of our common stock at the average market price using the proceeds of approximately $ 251.3 million, adjusted for costs to borrow. For the year ended December 31, 2021, the impact to our weighted-average shares-diluted was approximately 916,000 weighted-average incremental shares. For the year ended December 31, 2020, 819,000 weighted-average incremental shares of our common stock were excluded from the computation of our weighted-average shares - diluted, as the impact was anti-dilutive.
We include unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents as “participating securities” pursuant to the two-class method. The resulting classes are our common stock and restricted stock. Our forward equity agreement is not considered a participating security and, therefore, is not included in the computation of earnings per share using the two-class method. For the years ended December 31, 2021, 2020 and 2019, all of our earnings were distributed and the calculated earnings per share amount would be the same for all classes.
102
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the years ended December 31, 2021, 2020 and 2019, respectively (in thousands, except per share data):
Year Ended December 31,
2021 2020 2019
Numerator:
Net income
$ 99,784 $ 53,508 $ 30,758
Net income attributable to non-controlling interests ( 1,768 ) ( 890 ) ( 604 )
Net income attributable to common stockholders $ 98,016 $ 52,618 $ 30,154
Denominator:
Weighted average shares outstanding - basic 219,439 218,078 205,720
Dilutive shares - OP Units convertible into common stock 3,860 3,588 3,885
Dilutive effect of forward equity sales agreement 916 — —
Adjusted weighted average shares outstanding - diluted 224,215 221,666 209,605
Earnings per common share - basic
Net income attributable to common stockholders
$ 0.45 $ 0.24 $ 0.15
Earnings per common share - diluted
Net income attributable to common stockholders
$ 0.44 $ 0.24 $ 0.14
14. Per Unit Data of HTALP
During the year ended December 31, 2021, we issued approximately 9.4 million shares of our common stock under our ATM for net proceeds of approximately $ 251.3 million, adjusted for costs to borrow equating to a net price to us of $ 26.68 per share of common stock. Refer to Note 13 - Per Share Data of HTA to our consolidated financial statements for a more detailed discussion related to our forward equity agreements.
The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the years ended December 31, 2021, 2020 and 2019, respectively (in thousands, except per unit data):
Year Ended December 31,
2021 2020 2019
Numerator:
Net income
$ 99,784 $ 53,508 $ 30,758
Net income attributable to non-controlling interests — — ( 66 )
Net income attributable to common OP unitholders $ 99,784 $ 53,508 $ 30,692
Denominator:
Weighted average units outstanding - basic 223,299 221,666 209,605
Dilutive units - OP Units convertible into common units — — —
Dilutive effect of forward equity sales agreement 916 — —
Adjusted weighted average OP units outstanding - diluted 224,215 221,666 209,605
Earnings per common unit - basic:
Net income attributable to common OP unitholders $ 0.45 $ 0.24 $ 0.15
Earnings per common unit - diluted:
Net income attributable to common OP unitholders $ 0.45 $ 0.24 $ 0.15
103
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
15. Supplemental Cash Flow Information
The following is the supplemental cash flow information for the years ended December 31, 2021, 2020 and 2019, respectively (in thousands):
Year Ended December 31,
2021 2020 2019
Supplemental Disclosure of Cash Flow Information:
Interest paid, net of capitalized interest $ 80,367 $ 83,375 $ 94,668
Cash paid for operating leases 15,108 12,465 11,842
Supplemental Disclosure of Noncash Investing and Financing Activities:
Accrued capital and development expenditures $ 12,696 $ 31,807 $ 6,381
Conversion of notes receivable to investments in real estate 1,142 — —
Extinguishment of finance ground lease from land acquisition — 1,710 —
Dividend distributions declared, but not paid
75,723 71,423 69,468
Issuance of OP Units in HTALP
— — 2,603
Issuance of OP Units in HTALP in connection with an acquisition
35,785 — 2,000
Note receivable retired in connection with an acquisition
— 6,000 —
Redemption of non-controlling interest 6,354 9,019 7,527
ROU assets obtained in exchange for lease obligations
8,798 4,373 200,879
16. Treatment of Dividends of HTA
The following is the income tax treatment of dividend distributions for the years ended December 31, 2021, 2020 and 2019 (in per share):
Year Ended December 31,
2021 2020 2019
Ordinary income $ 0.7920 $ 0.6976 $ 0.6405
Return of capital 0.4930 0.5582 0.6045
Capital gain 0.0000 0.0092 0.0000
Total $ 1.2850 $ 1.2650 $ 1.2450
17. Selected Quarterly Financial Data of HTA (Unaudited)
The following is the selected quarterly financial data of HTA for 2021 and 2020. We believe that all necessary adjustments, consisting of only normal recurring adjustments, have been included (in thousands, except per share data).
Quarter Ended (1)
2021 March 31 June 30 September 30 December 31
Revenues $ 191,493 $ 188,615 $ 191,262 $ 195,703
Net income 22,393 38,739 22,042 16,610
Net income attributable to common stockholders 22,030 38,011 21,672 16,303
Earnings per common share - basic:
Net income attributable to common stockholders $ 0.10 $ 0.17 $ 0.10 $ 0.07
Earnings per common share - diluted:
Net income attributable to common stockholders $ 0.10 $ 0.17 $ 0.10 $ 0.07
(1) The sum of the individual quarterly amounts may not agree to the annual amounts included in the accompanying consolidated statements of operations due to rounding.
104
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
Quarter Ended (1)
2020 March 31 June 30 September 30 December 31
Revenues $ 185,776 $ 178,845 $ 187,326 $ 187,018
Net income (loss) 18,208 13,725 ( 6,932 ) 28,507
Net income (loss) attributable to common stockholders 17,901 13,489 ( 6,827 ) 28,055
Earnings per common share - basic:
Net income (loss) attributable to common stockholders $ 0.08 $ 0.06 $ ( 0.03 ) $ 0.13
Earnings per common share - diluted:
Net income (loss) attributable to common stockholders $ 0.08 $ 0.06 $ ( 0.03 ) $ 0.13
(1) The sum of the individual quarterly amounts may not agree to the annual amounts included in the accompanying consolidated statements of operations due to rounding.
105
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
18. Selected Quarterly Financial Data of HTALP (Unaudited)
The following is the selected quarterly financial data of HTALP for 2021 and 2020. We believe that all necessary adjustments, consisting of only normal recurring adjustments, have been included (in thousands, except per unit data).
Quarter Ended (1)
2021 March 31 June 30 September 30 December 31
Revenues $ 191,493 $ 188,615 $ 191,262 $ 195,703
Net income 22,393 38,739 22,042 16,610
Net income attributable to common OP unitholders 22,393 38,739 22,042 16,610
Earnings per common OP unit - basic:
Net income attributable to common OP unitholders $ 0.10 $ 0.17 $ 0.10 $ 0.07
Earnings per common OP unit - diluted:
Net income attributable to common OP unitholders $ 0.10 $ 0.17 $ 0.10 $ 0.07
(1) The sum of the individual quarterly amounts may not agree to the annual amounts included in the accompanying consolidated statements of operations due to rounding.
Quarter Ended (1)
2020 March 31 June 30 September 30 December 31
Revenues $ 185,776 $ 178,845 $ 187,326 $ 187,018
Net income (loss) 18,208 13,725 ( 6,932 ) 28,507
Net income (loss) attributable to common OP unitholders 18,208 13,725 ( 6,932 ) 28,507
Earnings per common OP unit - basic:
Net income (loss) attributable to common OP unitholders $ 0.08 $ 0.06 $ ( 0.03 ) $ 0.13
Earnings per common OP unit - diluted:
Net income (loss) attributable to common OP unitholders $ 0.08 $ 0.06 $ ( 0.03 ) $ 0.13
(1) The sum of the individual quarterly amounts may not agree to the annual amounts included in the accompanying consolidated statements of operations due to rounding.
19. Subsequent Events
Merger with Healthcare Realty Trust Incorporated
On February 28, 2022, Healthcare Trust of America, Inc. (the “Company”), a Maryland corporation, Healthcare Trust of America Holdings, LP, a Delaware limited partnership (the “Company OP”) of which the Company is the sole general partner, HR Acquisition 2, LLC, a Maryland limited liability company and a direct, wholly owned subsidiary of the Company (“Merger Sub”), and Healthcare Realty Trust Incorporated, a Maryland corporation (“HR”), entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”). Upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into HR, with HR surviving the merger (the “Merger”).
Prior to the effective time of the Merger (the “Effective Time”), the Company and the Company OP will take all requisite action so that, as of immediately after the Effective Time, the existing amended and restated agreement of limited partnership of the Company OP will be amended and restated to update the redemption provisions therein to account for the Merger Consideration described below.
The board of directors of the Company (the “Company Board”) has unanimously approved the Merger Agreement, the Merger and the other transactions contemplated by the Merger Agreement. The Merger is intended to qualify as a “reorganization” within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended.
Pursuant to the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each outstanding share of Common Stock, $ 0.01 par value per share, of HR (“HR Common Stock”) will be converted into the right to receive 1.0 (the “Exchange Ratio”) share of Class A Common Stock, $ 0.01 par value per share, of the Company (“Company Common Stock” and, such consideration, the “Merger Consideration”). Subject to the closing of the Merger and the other transactions contemplated therein, the holders of shares of Company Common Stock issued and outstanding on the last business day prior to the closing date of the Merger will receive a special distribution in the amount of $ 4.82 in cash per share of Company Common Stock held on such date (the “Special Distribution Payment”).
Once the conditions to close the Merger have been satisfied or waived, the Merger Agreement requires HR and the Company to exchange irrevocable certifications that all such closing conditions have been satisfied or waived. At such time, the Company OP will transfer or cause the transfer, on the business day before the Effective Time, to HR or its designees certain of the Company OP’s assets
106
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
as specified by HR for a cash purchase price equal to the reasonably equivalent fair market value of the assets transferred. To the extent the net proceeds to the Company of the asset transfer or joint venture transactions relating to such assets are insufficient to pay the full amount of the Special Distribution Payment, the Merger Agreement requires the Company to utilize new financing to fund the balance of the Special Distribution Payment. The Company has obtained a commitment letter from JPMorgan Chase Bank, N.A. for a $ 1.7 billion bridge financing facility.
Each option to acquire HR Common Stock that is outstanding immediately prior to the Effective Time will by virtue of the Merger be assumed by the Company with the same terms and conditions of such options immediately prior to the Effective Time, except that each HR stock option will be exercisable (or will become exercisable in accordance with its terms) for the same number of shares of Company Common Stock. Each share of restricted HR common stock and each right of any kind, contingent or accrued, to receive shares of HR Common Stock or benefits measured in whole or in part by the value of a number of shares of HR Common Stock granted by HR outstanding immediately prior to the Effective Time will become an award, on the same terms and conditions as applied to each such HR stock-based award immediately prior to the Effective Time, with respect to the number of shares of Company Common Stock that is equal to the number of shares of HR Common Stock subject to the HR stock-based award immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the nearest full shares.
Each share of Company Common Stock subject to forfeiture conditions outstanding immediately prior to the Effective Time will vest in full as of immediately prior to the Effective Time with any Company restricted shares that were granted subject to performance-based vesting conditions treated assuming attainment of the target level of performance. Each such Company restricted share will be entitled to receive $ 4.82 in cash and any accrued but unpaid dividends with respect to such Company restricted share.
Pursuant to the Merger Agreement, the parties have agreed that following the closing of the Merger, the Company Board will consist of 14 members, nine of whom will be the directors of HR immediately prior to the Effective Time and four of whom will be individuals designated by the Company, consisting of W. Bradley Blair II, Vicki U. Booth, Jay P. Leupp and Constance Moore. John Knox Singleton, currently Chairman of the HR board of directors, will be Chairman of the Company Board and W. Bradley Blair, II, currently Chairman of the Company Board, will be appointed Vice Chairman.
Each of the Company and HR have made certain customary representations and warranties in the Merger Agreement and have agreed to customary covenants, including covenants that each party conduct its business in the ordinary course of business during the period between execution of the Merger Agreement and the Effective Time and covenants prohibiting each party from engaging in certain kinds of activities during such period without the consent of the other party.
The Merger Agreement provides that, during the period from the date of the Merger Agreement until the Effective Time, subject to customary exceptions, the Company and HR will be subject to certain restrictions on (a) soliciting proposals relating to certain alternative transactions, (b) entering into discussions or negotiating or providing non-public information in connection with any proposal for an alternative transaction from a third party, (c) approving or entering into any agreements providing for any such alternative transaction, or (d) agreeing to or proposing publicly to do any of the foregoing. Notwithstanding these “no-shop” restrictions, prior to obtaining the approval of HR stockholders and approval of the Company stockholders, under specified circumstances, the Company Board and the board of directors of HR, respectively, may change their recommendations with respect to the Merger, and the Company and HR may each also terminate the Merger Agreement to accept a superior proposal upon payment of the termination fees described below.
In accordance with the Merger Agreement, the Company will prepare and file with the U.S. Securities and Exchange Commission (the “SEC”) a Form S-4 registering shares of Company Common Stock issuable in the Merger, and the parties will prepare a joint proxy statement with respect to the special meeting of the Company’s stockholders to be convened for purposes of approving the issuance of shares of Company Common Shares in the Merger and the special meeting of HR’s stockholders to be convened for purposes of approving the Merger Agreement and the Merger. The joint proxy statement will be included in the Form S-4 and will contain, subject to certain exceptions, the recommendation of the Company Board that the Company’s stockholders vote in favor of the issuance of shares of Company Common Shares in the Merger and the recommendation of the HR board of directors that HR’s stockholders vote in favor of approval of the Merger Agreement and the Merger.
The completion of the Merger is subject to customary conditions, including, among others: (i) approval by the Company’s stockholders and approval by HR’s stockholders, (ii) the effectiveness of the Form S-4, (iii) the absence of injunctions, restraints or government restrictions, (iv) approval by the New York Stock Exchange for listing of the shares of Company Common Stock issuable in the Merger, (v) the absence of a material adverse effect on either the Company or HR, (vi) the accuracy of each party’s representations and warranties and performance in all material respects of each party’s covenants and agreements in the Merger Agreement, (vii) the receipt of tax opinions relating to the status as a real estate investment trust (“REIT”) of each company and the tax-free nature of the transaction, and (viii) other customary conditions specified in the Merger Agreement.
The Merger Agreement may be terminated under certain circumstances, including by either party (i) if the Merger has not been consummated on or before August 28, 2022, (ii) if a final and non-appealable order is entered, or other action is taken permanently restraining or prohibiting the transaction, (iii) upon a failure of either party to obtain approval of its stockholders, (iv) upon a material, uncured breach by the other party that would cause the closing conditions not to be satisfied, subject to a 30-day cure period, (v) if the other party’s board makes an adverse recommendation change with respect to the transaction, or (vi) prior to obtaining approval of its
107
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
stockholders, and upon payment of the applicable termination fee, in order to enter into a definitive agreement with a third party with respect to a superior acquisition proposal.
If the Merger Agreement is terminated because (i) a party’s board changes its recommendation in favor of the transactions contemplated by the Merger Agreement, (ii) a party terminates the Merger Agreement to enter into a definitive agreement with a third party with respect to a superior acquisition proposal, or (iii) a party consummates or enters into an agreement for an alternative transaction within 12 months following termination under certain circumstances, such party must pay a termination fee to the other party; provided, further, that HR must also pay the Company a termination fee (plus reimburse the Company for its actual transaction expenses up to $ 5,000,000 ) if, on the business day immediately prior to the Outside Date, the proceeds of the asset transfer, any immediate asset transfer and the financing available to the Company pursuant to the Commitment Letter or if applicable any alternative financing are insufficient to pay the aggregate Special Distribution and any unpaid cash payment obligations of HR under the Merger Agreement (so long as such termination is not in material breach of the financing, financing cooperation and sale activity provisions of the Merger Agreement). The termination fee payable by HR to the Company in such circumstances is $ 163 million. The termination fee payable by the Company to HR in such circumstances is $ 291 million. The actual amount of each termination fee described above is subject to an escrow and adjustment mechanism for REIT compliance purposes to provide for a lesser amount if necessary to be paid to the receiving party without causing such party to fail to meet its REIT requirements for such year.
The Merger Agreement also provides that if the Company’s stockholders have approved the transactions contemplated by the Merger Agreement, but the Merger Agreement is terminated by the Company because HR’s stockholders vote against the transactions contemplated by the Merger Agreement, HR must pay the Company a fixed expense reimbursement base amount of $ 25,000,000 , plus reimburse the Company for its actual transaction expenses up to $ 5,000,000 . The Merger Agreement also provides that if HR’s stockholders have approved the transactions contemplated by the Merger Agreement, but the Merger Agreement is terminated by HR because the Company’s stockholders vote against the transactions contemplated by the Merger Agreement, the Company must pay HR a fixed expense reimbursement base amount of $ 25,000,000 , plus reimburse the Company for its actual transaction expenses up to $ 5,000,000 ).
The Merger Agreement contains customary representations, warranties and covenants by each party. The Merger is subject to certain conditions which are set forth in the Merger Agreement, including the approval of both companies’ stockholders. The boards of directors of the Company and HR have unanimously approved the Merger Agreement. The Merger is expected to close mid-2022.
108
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)
The following schedule presents our total real estate investments and accumulated depreciation for our portfolio as of December 31, 2021 (in thousands):
Initial Cost to Company Cost
Capitalized
Subsequent
to
Acquisition (a) Gross Amount at Which
Carried at Close of Period
Encumbrances Land Buildings,
Improvements and
Fixtures Land Buildings,
Improvements and
Fixtures Total (c) Accumulated
Depreciation (f)
Date of Construction Date
Acquired Life on Which Building Depreciation in Income Statement is Computed (h)
Operating Properties:
Shelby MOBs Alabaster, AL $ — $ — $ 25,095 $ 2,686 $ — $ 27,781 $ 27,781 $ ( 5,390 ) 1995-1998 2016 36
Simon Williamson Clinic Birmingham, AL — — 25,689 ( 156 ) — 25,533 25,533 ( 4,489 ) 2007 2016 36
Jasper Jasper, AL — — 5,973 325 — 6,298 6,298 ( 1,563 ) 1979 2016 25
Phoenix Med Center Glendale, AZ — 453 2,768 841 453 3,609 4,062 ( 1,311 ) 1989 2011 39
Thunderbird MOP Glendale, AZ — 3,842 19,679 2,198 3,842 21,877 25,719 ( 9,597 ) 1976-1987 2007 39
Peoria MOB Peoria, AZ — 605 4,394 2,248 605 6,642 7,247 ( 2,115 ) 2000 2010 39
Baptist MC Phoenix, AZ — — 12,637 3,661 — 16,298 16,298 ( 6,113 ) 1973 2008 39
Desert Ridge MOB Phoenix, AZ — — 27,738 2,690 — 30,428 30,428 ( 9,779 ) 2004-2006 2011 39
Dignity Phoenix MOBs Phoenix, AZ — — 66,106 1,342 — 67,448 67,448 ( 10,483 ) 1984-1997 2017 20-39
Estrella Med Center Phoenix, AZ — — 24,703 2,142 — 26,845 26,845 ( 9,240 ) 2004 2010 39
Sun City Boswell MOBs Sun City, AZ — — 12,642 4,464 — 17,106 17,106 ( 6,672 ) 1971-2001 2009 39
Sun City Boswell West Sun City, AZ — — 6,610 1,913 — 8,523 8,523 ( 3,354 ) 1992 2009 39
Sun City Webb MP Sun City, AZ — — 16,188 4,021 — 20,209 20,209 ( 7,808 ) 1997-2004 2009 39
Sun City West MOBs Sun City, AZ — 744 13,466 4,160 744 17,626 18,370 ( 6,936 ) 1987-2002 2009 39
Gateway Med Plaza Tucson, AZ — — 14,005 565 — 14,570 14,570 ( 4,629 ) 2008 2010 39
Tucson Academy MOP Tucson, AZ — 1,193 6,107 1,396 1,193 7,503 8,696 ( 3,071 ) 1978 2008 39
Tucson Desert Life MOP Tucson, AZ — 1,309 17,572 6,466 1,309 24,038 25,347 ( 10,468 ) 1980 -1984 2007 39
Bakersfield Medical Office Building Bakersfield, CA — — — 28,695 — 28,695 28,695 ( 293 ) 2021 2020 39
Dignity Mercy MOBs Bakersfield, CA — — 15,207 ( 240 ) — 14,967 14,967 ( 2,144 ) 1992 2017 35
5995 Plaza Drive Cypress, CA — 5,109 17,961 2,703 5,109 20,664 25,773 ( 7,860 ) 1986 2008 39
Dignity Glendale MOB Glendale, CA — — 7,244 257 — 7,501 7,501 ( 1,530 ) 1980 2017 30
3rd Street MOB Los Angeles, CA — 10,603 63,419 2,070 10,603 65,489 76,092 ( 5,750 ) 1990 2019 39
Mission Medical Center MOBs Mission Viejo, CA — 21,911 117,672 7,416 21,911 125,088 146,999 ( 18,184 ) 1972-1985 2016 39
Dignity Northridge MOBs Northridge, CA — — 21,467 1,250 — 22,717 22,717 ( 3,657 ) 1979-1994 2017 30-35
San Luis Obispo MOB San Luis Obispo, CA — — 11,900 985 — 12,885 12,885 ( 4,169 ) 2009 2010 39
Facey MOB Santa Clarita, CA — 6,452 5,586 19,641 6,452 25,227 31,679 ( 3,447 ) 2018 2017 39
Dignity Marian MOBs Santa Maria, CA — — 13,646 726 — 14,372 14,372 ( 2,940 ) 1994-1995 2017 17-38
Premier Health Plaza Colorado Springs, CO — 1,672 10,954 113 1,668 11,071 12,739 ( 307 ) 2001 2021 39
Rampart MOB Denver, CO — 3,794 13,077 434 3,794 13,511 17,305 ( 1,017 ) 1983-1995 2019 39
SCL Health MOBs Denver, CO — 11,652 104,327 10,372 11,652 114,699 126,351 ( 14,592 ) 2015-2017 2017 39
Hampden Place MOB Englewood, CO — 3,032 12,553 475 3,032 13,028 16,060 ( 4,095 ) 2004 2009 39
Highlands Ranch MOP Highlands Ranch, CO — 2,240 10,426 8,385 2,240 18,811 21,051 ( 8,692 ) 1983-1985 2007 39
Lone Tree Medical Office Buildings Lone Tree, CO — 3,736 29,546 2,313 3,736 31,859 35,595 ( 7,115 ) 2004-2008 2014 38
Lincoln Medical Center Parker, CO — 5,142 28,638 1,682 5,142 30,320 35,462 ( 7,894 ) 2008 2013 39
109
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
SCHEDULE III — REAL ESTATE AND ACCUMULATED DEPRECIATION
Initial Cost to Company Cost
Capitalized
Subsequent
to
Acquisition (a) Gross Amount at Which
Carried at Close of Period
Encumbrances Land Buildings,
Improvements and
Fixtures Land Buildings,
Improvements and
Fixtures Total (c) Accumulated
Depreciation (f)
Date of Construction Date
Acquired Life on Which Building Depreciation in Income Statement is Computed (h)
80 Fisher Avon, CT $ — $ — $ 5,094 $ 1 $ — $ 5,095 $ 5,095 $ ( 1,414 ) 2008 2016 39
533 Cottage - Northwestern Bloomfield, CT — 726 3,964 ( 527 ) 726 3,437 4,163 ( 749 ) 1955 2016 35
Northwestern MOBs Bloomfield, CT — 1,369 6,287 732 1,369 7,019 8,388 ( 1,865 ) 1985 2016 35
406 Farmington Farmington, CT — 379 3,509 3 379 3,512 3,891 ( 692 ) 1988 2016 39
704 Hebron Glastonbury, CT — 2,223 6,544 20 2,223 6,564 8,787 ( 1,575 ) 2001 2016 37
Gateway MOBs Glastonbury, CT — 11,328 41,320 10,291 13,448 49,491 62,939 ( 10,190 ) 2007-2017 2016-2017 39
Hamden MOB Hamden, CT — 4,925 36,835 69 4,925 36,904 41,829 ( 2,356 ) 1970-1972 2019 39
Haynes MOBs Manchester, CT — 1,100 14,620 6 1,100 14,626 15,726 ( 2,681 ) 2007-2010 2016 39
Pomeroy MOBs Meriden, CT — 1,774 10,078 ( 48 ) 1,774 10,030 11,804 ( 2,412 ) 2009-2011 2016 39
Saybrook MOBs Middleton, CT — — 10,314 887 — 11,201 11,201 ( 2,711 ) 1989 2016 28
Yale Long Wharf New Haven, CT — 9,367 58,691 7,707 7,791 67,974 75,765 ( 17,824 ) 1977 2016 30
Devine MOBs North Haven, CT — 3,606 27,278 1,708 3,606 28,986 32,592 ( 5,301 ) 2006-2017 2016-2017 35
Evergreen MOBs South Windsor, CT — 5,565 25,839 ( 81 ) 5,833 25,490 31,323 ( 4,845 ) 2006-2011 2016 39
Westport Center Westport, CT — 3,311 13,296 843 3,311 14,139 17,450 ( 1,364 ) 1985 2019 39
Day Hill MOBs Windsor, CT — 3,980 7,055 34 3,980 7,089 11,069 ( 2,166 ) 1990-1999 2016 30
Clint Moore Medical Facility Boca Raton, FL — 20,051 27,157 64 20,072 27,200 47,272 ( 384 ) 1996 2021 39
Riverside MOB Bradenton, FL — 2,230 7,689 354 2,230 8,043 10,273 ( 1,886 ) 1980 2016 25
Brandon MOP Brandon, FL — 901 6,946 867 901 7,813 8,714 ( 2,807 ) 1997 2008 39
McMullen MOB Clearwater, FL — 3,470 12,621 ( 613 ) 3,470 12,008 15,478 ( 2,907 ) 2009 2014 39
Orlando Rehab Hospital Edgewood, FL — 2,600 20,256 3,000 2,600 23,256 25,856 ( 8,425 ) 2007 2010 39
Palmetto MOB Hialeah, FL — — 15,512 5,487 — 20,999 20,999 ( 7,775 ) 1980 2013 39
Palmetto II Hialeah, FL — — 51,480 75 — 51,555 51,555 ( 1,673 ) 1992 2020 39
East FL Senior Jacksonville Jacksonville, FL — 4,291 9,220 ( 736 ) 4,291 8,484 12,775 ( 3,647 ) 1985 2007 39
King Street MOB Jacksonville, FL — — 7,232 86 — 7,318 7,318 ( 2,445 ) 2007 2010 39
Jupiter MP Jupiter, FL — 1,204 11,778 1,283 1,204 13,061 14,265 ( 3,336 ) 1996-1997 2013 39
Central FL SC Lakeland, FL — 768 3,002 511 768 3,513 4,281 ( 1,549 ) 1995 2008 39
Vista Pro Center MOP Lakeland, FL — 1,082 3,587 569 1,082 4,156 5,238 ( 1,582 ) 1996-1999 2007-2008 39
Largo Medical Center Largo, FL — — 51,045 660 — 51,705 51,705 ( 11,897 ) 2009 2013 39
Largo MOP Largo, FL — 729 8,908 1,496 729 10,404 11,133 ( 4,234 ) 1975-1986 2008 39
FL Family Medical Center Lauderdale Lakes, FL — — 4,257 1,271 — 5,528 5,528 ( 2,519 ) 1978 2013 39
Northwest Medical Park Margate, FL — — 9,525 ( 297 ) 5 9,223 9,228 ( 2,138 ) 2009 2013 39
Coral Reef Miami, FL — 1,160 — 18,454 1,160 18,454 19,614 ( 343 ) 2021 2017 39
North Shore MOB Miami, FL — — 4,942 1,592 — 6,534 6,534 ( 2,889 ) 1978 2013 39
Sunset Professional and Kendall MOBs Miami, FL — 11,855 13,633 6,679 11,855 20,312 32,167 ( 7,506 ) 1954-2006 2014 27
Commons V MOB Naples, FL — 4,173 9,070 2,788 4,173 11,858 16,031 ( 4,642 ) 1990 2007 39
Orlando Lake Underhill MOB Orlando, FL — — 8,515 428 — 8,943 8,943 ( 2,837 ) 2000 2010 39
Florida Hospital MOBs Orlando, Sebring and Tampa, FL — — 151,647 3,185 — 154,832 154,832 ( 21,818 ) 2006-2012 2017 39
Orlando Oviedo MOB Oviedo, FL — — 5,711 926 — 6,637 6,637 ( 2,364 ) 1998 2010 39
Heart & Family Health MOB Port St. Lucie, FL — 686 8,102 15 686 8,117 8,803 ( 2,248 ) 2008 2013 39
St. Lucie MC Port St. Lucie, FL — — 6,127 ( 41 ) — 6,086 6,086 ( 1,473 ) 2008 2013 39
East FL Senior Sunrise Sunrise, FL — 2,947 12,825 ( 1,006 ) 2,947 11,819 14,766 ( 4,641 ) 1989 2007 39
Tallahassee Rehab Hospital Tallahassee, FL — 7,142 18,691 2,400 7,142 21,091 28,233 ( 7,903 ) 2007 2010 39
Optimal MOBs Tampa, FL — 4,002 69,824 552 4,002 70,376 74,378 ( 10,921 ) 2005-2015 2017 39
Tampa Medical Village MOB Tampa, FL — 3,627 14,806 1,295 3,627 16,101 19,728 ( 2,906 ) 2003 2017 35
110
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
SCHEDULE III — REAL ESTATE AND ACCUMULATED DEPRECIATION — (Continued)
Initial Cost to Company Cost
Capitalized
Subsequent
to
Acquisition (a) Gross Amount at Which
Carried at Close of Period
Encumbrances Land Buildings,
Improvements and
Fixtures Land Buildings,
Improvements and
Fixtures Total (c) Accumulated
Depreciation (f)
Date of Construction Date
Acquired Life on Which Building Depreciation in Income Statement is Computed (h)
VA MOBs Tampa, FL $ — $ 17,802 $ 80,154 $ 732 $ 17,802 $ 80,886 $ 98,688 $ ( 11,226 ) 2013 2017 39
FL Ortho Institute Temple Terrace, FL — 2,923 17,647 ( 1 ) 2,923 17,646 20,569 ( 6,021 ) 2001-2003 2010 39
Wellington MAP III Wellington, FL — — 10,511 31 — 10,542 10,542 ( 3,288 ) 2006 2010 39
Victor Farris MOB West Palm Beach, FL — — 23,052 11,965 — 35,017 35,017 ( 9,022 ) 1988 2013 39
East FL Senior Winter Park Winter Park, FL — 2,840 12,825 ( 1,023 ) 2,840 11,802 14,642 ( 4,872 ) 1988 2007 39
Camp Creek Med Center Atlanta, GA — 2,961 19,688 1,371 2,961 21,059 24,020 ( 7,593 ) 2006 - 2010 2010-2012 39
Camp Creek MOB Atlanta, GA — 328 12,539 — 328 12,539 12,867 ( 875 ) 2018 2019 39
North Atlanta MOBs Atlanta, GA — — 41,836 1,621 — 43,457 43,457 ( 6,249 ) 2011-2012 2017 39
Paces Pavilion Atlanta, GA — 3,670 16,328 27 3,670 16,355 20,025 — 1996 2021 39
Augusta Rehab Hospital Augusta, GA — 1,059 20,899 — 1,059 20,899 21,958 ( 6,779 ) 2007 2010 39
Austell Medical Park Austell, GA — 432 4,057 ( 160 ) 432 3,897 4,329 ( 1,113 ) 2007 2013 39
Harbin Clinic MOBs Cedartown, Rome and Summerville, GA — 7,097 112,155 ( 11,230 ) 7,097 100,925 108,022 ( 17,790 ) 1960-2010 2017 30-39
Decatur MP Decatur, GA — 3,166 6,862 1,303 3,166 8,165 11,331 ( 2,954 ) 1976 2008 39
Yorktown MC Fayetteville, GA — 2,802 12,502 3,967 2,802 16,469 19,271 ( 6,766 ) 1987 2007 39
Gwinett MOP Lawrenceville, GA — 1,290 7,246 4,525 1,290 11,771 13,061 ( 5,467 ) 1985 2007 39
Marietta Health Park Marietta, GA — 1,276 12,197 3,198 1,276 15,395 16,671 ( 5,436 ) 2000 2008 39
WellStar Tower MOB Marietta, GA — 748 13,528 321 748 13,849 14,597 ( 2,962 ) 2007 2015 39
Shakerag MC Peachtree City, GA — 743 3,290 1,130 743 4,420 5,163 ( 2,307 ) 1994 2007 39
Overlook at Eagle's Landing Stockbridge, GA — 638 6,685 581 638 7,266 7,904 ( 2,653 ) 2004 2010 39
SouthCrest MOP Stockbridge, GA — 4,260 14,636 2,257 4,260 16,893 21,153 ( 7,061 ) 2005 2008 39
Cherokee Medical Center Woodstock, GA — — 16,558 990 — 17,548 17,548 ( 4,262 ) 2001 2015 35
Honolulu MOB Honolulu, HI — — 27,336 3,132 — 30,468 30,468 ( 6,595 ) 1997 2014 35
Kapolei Medical Park Kapolei, HI — — 16,253 643 — 16,896 16,896 ( 4,237 ) 1999 2014 35
North Curtis Road Boise, ID — 382 5,995 12 382 6,007 6,389 ( 462 ) 1983 2020 39
Eagle Road MOB Meridian, ID — 666 9,636 ( 146 ) 666 9,490 10,156 ( 1,004 ) 2000 2019 39
Chicago MOBs Chicago, IL — 7,723 129,520 1,151 7,723 130,671 138,394 ( 16,824 ) 2006-2017 2017 38-39
Streeterville Center MOB Chicago, IL — 4,223 35,008 139 4,223 35,147 39,370 ( 2,554 ) 1968 2019 39
Rush Oak Park MOB Oak Park, IL — 1,096 38,550 ( 2,667 ) 1,096 35,883 36,979 ( 8,975 ) 2000 2012 38
Brownsburg MOB Brownsburg, IN — 431 639 641 431 1,280 1,711 ( 531 ) 1989 2008 39
Athens SC Crawfordsville, IN — 381 3,575 417 381 3,992 4,373 ( 1,670 ) 2000 2007 39
Crawfordsville MOB Crawfordsville, IN — 318 1,899 260 318 2,159 2,477 ( 907 ) 1997 2007 39
Deaconess Clinic Downtown Evansville, IN — 1,748 21,963 77 1,748 22,040 23,788 ( 8,675 ) 1952-1967 2010 39
Deaconess Clinic Westside Evansville, IN — 360 3,265 356 360 3,621 3,981 ( 1,413 ) 2005 2010 39
Dupont MOB Fort Wayne, IN — — 8,246 1,412 — 9,658 9,658 ( 2,209 ) 2004 2013 39
Ft. Wayne MOB Ft. Wayne, IN — — 6,579 ( 243 ) — 6,336 6,336 ( 1,940 ) 2008 2009 39
Community MP Indianapolis, IN — 560 3,581 821 560 4,402 4,962 ( 1,719 ) 1995 2008 39
Eagle Highlands MOP Indianapolis, IN — 2,216 11,154 8,269 2,216 19,423 21,639 ( 10,226 ) 1988-1989 2008 39
Epler Parke MOP Indianapolis, IN — 1,556 6,928 2,095 1,556 9,023 10,579 ( 3,807 ) 2002-2003 2007-2008 39
Glendale Professional Plaza Indianapolis, IN — 570 2,739 1,697 570 4,436 5,006 ( 2,332 ) 1993 2008 39
111
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
SCHEDULE III — REAL ESTATE AND ACCUMULATED DEPRECIATION — (Continued)
Initial Cost to Company Cost
Capitalized
Subsequent
to
Acquisition (a) Gross Amount at Which
Carried at Close of Period
Encumbrances Land Buildings,
Improvements and
Fixtures Land Buildings,
Improvements and
Fixtures Total (c) Accumulated
Depreciation (f)
Date of Construction Date
Acquired Life on Which Building Depreciation in Income Statement is Computed (h)
MMP Eagle Highlands Indianapolis, IN $ — $ 1,044 $ 13,548 $ 3,914 $ 1,044 $ 17,462 $ 18,506 $ ( 6,969 ) 1993 2008 39
MMP East Indianapolis, IN — 1,236 9,840 3,374 1,236 13,214 14,450 ( 6,364 ) 1996 2008 39
MMP North Indianapolis, IN — 1,518 15,460 6,210 1,427 21,761 23,188 ( 9,521 ) 1995 2008 39
MMP South Indianapolis, IN — 1,127 10,414 2,333 1,127 12,747 13,874 ( 5,430 ) 1994 2008 39
Southpointe MOP Indianapolis, IN — 2,190 7,548 1,529 2,190 9,077 11,267 ( 4,016 ) 1996 2007 39
St. Vincent MOB Indianapolis, IN — 2,964 23,352 49 2,964 23,401 26,365 ( 3,773 ) 2007 2017 35
Kokomo MOP Kokomo, IN — 1,779 9,614 2,450 1,779 12,064 13,843 ( 5,260 ) 1992-1994 2007 39
Deaconess Clinic Gateway Newburgh, IN — — 10,952 26 — 10,978 10,978 ( 3,844 ) 2006 2010 39
Community Health Pavilion Noblesville, IN — 5,560 28,988 1,658 5,560 30,646 36,206 ( 8,124 ) 2009 2015 39
Zionsville MC Zionsville, IN — 655 2,877 1,152 664 4,020 4,684 ( 1,825 ) 1992 2008 39
Nashoba Valley Med Center MOB Ayer, MA — — 5,529 313 299 5,543 5,842 ( 1,888 ) 1976-2007 2012 31
670 Albany Boston, MA — — 104,365 ( 1,795 ) — 102,570 102,570 ( 17,428 ) 2005 2015 39
Tufts Medical Center Boston, MA — 32,514 109,180 9,778 32,514 118,958 151,472 ( 32,158 ) 1924-2015 2014 35
St. Elizabeth's Med Center Brighton, MA — — 20,929 3,627 1,379 23,177 24,556 ( 7,529 ) 1965-2013 2012 31
Good Samaritan MOBs Brockton , MA — — 15,887 2,127 144 17,870 18,014 ( 5,477 ) 1980-2007 2012 31
Pearl Street MOBs Brockton, MA — 4,714 18,193 1,465 4,714 19,658 24,372 ( 4,266 ) 1966-2004 2016 39
Carney Hospital MOB Dorchester, MA — — 7,250 813 530 7,533 8,063 ( 2,450 ) 1978 2012 31
St. Anne's Hospital MOB Fall River, MA — — 9,304 130 40 9,394 9,434 ( 2,381 ) 2011 2012 31
Norwood Hospital MOB Foxborough, MA — — 9,489 536 2,295 7,730 10,025 ( 2,751 ) 1930-2000 2012 31
Holy Family Hospital MOB Methuen, MA — — 4,502 304 168 4,638 4,806 ( 1,872 ) 1988 2012 31
Morton Hospital MOB Taunton, MA — — 15,317 1,910 502 16,725 17,227 ( 8,222 ) 1988 2012 31
Stetson MOB Weymouth, MA — 3,362 15,555 3,681 3,362 19,236 22,598 ( 6,409 ) 1900-1986 2015 20
Johnston Professional Building Baltimore, MD — — 21,481 423 — 21,904 21,904 ( 5,208 ) 1993 2014 35
Triad Tech Center Baltimore, MD — — 26,548 25 — 26,573 26,573 ( 8,499 ) 1989 2010 39
St. John Providence MOB Novi, MI — — 42,371 ( 195 ) — 42,176 42,176 ( 12,659 ) 2007 2012 39
Fort Road MOB St. Paul, MN — 1,571 5,786 1,468 1,571 7,254 8,825 ( 3,319 ) 1981 2008 39
Chesterfield Rehab Hospital Chesterfield, MO — 4,213 27,898 774 4,313 28,574 32,887 ( 11,410 ) 2007 2007 39
BJC West County MOB Creve Coeur, MO — 2,242 13,130 994 2,242 14,124 16,366 ( 5,494 ) 1978 2008 39
Winghaven MOB O'Fallon, MO — 1,455 9,708 1,645 1,455 11,353 12,808 ( 4,479 ) 2001 2008 39
BJC MOB St. Louis, MO — 304 1,554 ( 891 ) 304 663 967 ( 512 ) 2001 2008 39
Des Peres MAP II St. Louis, MO — — 11,386 36 — 11,422 11,422 ( 3,793 ) 2007 2010 39
Baptist Memorial MOB Oxford, MS — — 26,263 7,570 — 33,833 33,833 ( 3,759 ) 2017 2017 39
Medical Park of Cary Cary, NC — 2,931 20,305 38,308 2,931 58,613 61,544 ( 9,072 ) 1994 2010 39
Rex Cary MOB Cary, NC — 1,449 18,226 472 1,449 18,698 20,147 ( 3,696 ) 2002 2015 39
Tryon Office Center Cary, NC — 2,200 14,956 1,053 2,200 16,009 18,209 ( 3,659 ) 2002-2006 2015 39
Carolinas Health MOB Charlotte, NC — — 75,198 ( 1,072 ) — 74,126 74,126 ( 8,851 ) 2006 2017 39
Davidson MOB Davidson , NC — 1,188 8,556 98 1,188 8,654 9,842 ( 685 ) 2001 2019 39
Duke Fertility Center Durham, NC — 596 3,882 ( 106 ) 596 3,776 4,372 ( 569 ) 2006 2016 39
Duke Medical Plaza Durham, NC — 1,093 11,836 1,521 1,093 13,357 14,450 ( 261 ) 1988 2021 39
Hock Plaza II Durham, NC — 680 27,044 643 680 27,687 28,367 ( 4,569 ) 2006 2016 36
112
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
SCHEDULE III — REAL ESTATE AND ACCUMULATED DEPRECIATION — (Continued)
Initial Cost to Company Cost
Capitalized
Subsequent
to
Acquisition (a) Gross Amount at Which
Carried at Close of Period
Encumbrances Land Buildings,
Improvements and
Fixtures Land Buildings,
Improvements and
Fixtures Total (c) Accumulated
Depreciation (f)
Date of Construction Date
Acquired Life on Which Building Depreciation in Income Statement is Computed (h)
UNC Rex Holly Springs Holly Springs, NC $ — $ — $ 27,591 $ 11,082 $ — $ 38,673 $ 38,673 $ ( 4,347 ) 2011 2017 39
Huntersville Office Park Huntersville, NC — 5,376 67,125 2,331 5,376 69,456 74,832 ( 5,614 ) 1990-2001 2019 39
Rosedale MOB Huntersville, NC — 1,281 7,738 58 1,281 7,796 9,077 ( 698 ) 2005 2019 39
Medical Park MOBs Mooresville, NC — 1,771 13,266 9,982 2,141 22,878 25,019 ( 4,724 ) 2000-2005 2017 23
3100 Blue Ridge Raleigh, NC — 1,732 8,891 714 1,732 9,605 11,337 ( 3,016 ) 1985 2014 35
Raleigh Medical Center Raleigh, NC — 2,381 15,630 5,955 2,381 21,585 23,966 ( 8,311 ) 1989 2010 39
Sandy Forks MOB Raleigh, NC — 652 7,263 15 652 7,278 7,930 ( 950 ) 2016 2018 39
Sunset Ridge MOBs Raleigh, NC — 811 3,926 710 811 4,636 5,447 ( 585 ) 1999 2018 39
Piedmont MOB Statesville, NC — 1,024 13,911 41 1,024 13,952 14,976 ( 1,307 ) 1984 2020 39
NorthPark MOBs Wake Forest, NC — 2,098 13,921 2 2,098 13,923 16,021 ( 57 ) 1996-2008 2021 39
Hackensack MOB North Bergen, NJ — — 31,658 608 — 32,266 32,266 ( 4,003 ) 2014 2017 39
Mountain View MOB Las Cruces, NM — — 41,553 2,802 — 44,355 44,355 ( 6,064 ) 2003 2017 39
Santa Fe 440 MOB Santa Fe, NM — 842 7,448 ( 3,205 ) 842 4,243 5,085 ( 2,267 ) 1978 2010 39
San Martin MAP Las Vegas, NV — — 14,777 4,801 — 19,578 19,578 ( 7,882 ) 2007 2010 39
Madison Ave MOB Albany, NY — 83 2,759 151 83 2,910 2,993 ( 1,097 ) 1964-2008 2010 39
Patroon Creek HQ Albany, NY — 1,870 29,453 4,896 1,870 34,349 36,219 ( 12,451 ) 2001 2010 39
Patroon Creek MOB Albany, NY — 1,439 27,639 186 1,439 27,825 29,264 ( 9,013 ) 2007 2010 39
Washington Ave MOB Albany, NY — 1,699 18,440 1,023 1,699 19,463 21,162 ( 6,569 ) 1998-2000 2010 39
Putnam MOB Carmel, NY — — 24,216 326 — 24,542 24,542 ( 7,482 ) 2000 2010 39
Capital Region Health Park Latham, NY — 2,305 37,494 3,565 2,305 41,059 43,364 ( 14,672 ) 2001 2010 39
ACP MOB New York, NY — 53,265 62,873 505 53,265 63,378 116,643 ( 4,085 ) 1920-1988 2019 39
210 Westchester MOB White Plains, NY — 8,628 18,408 — 8,628 18,408 27,036 ( 5,225 ) 1981 2014 31
Westchester MOBs White Plains, NY — 17,274 41,865 11,930 17,274 53,795 71,069 ( 15,027 ) 1967-1983 2014 29
Kindred MOBs Avon, OH, Germantown, TN, Indianapolis, IN and Springfield, MO — 4,238 118,778 ( 101 ) 4,238 118,677 122,915 ( 16,338 ) 2013-2016 2017 39
Diley Ridge MOB Canal Winchester, OH — — 9,811 67 — 9,878 9,878 ( 2,128 ) 2010 2015 39
Good Sam MOB Cincinnati, OH — 1,825 9,966 ( 178 ) 1,825 9,788 11,613 ( 1,372 ) 2011 2017 39
TriHealth Cincinnati, OH — — 34,894 313 — 35,207 35,207 ( 4,484 ) 2016 2017 39
Market Exchange MOP Columbus, OH — 2,326 17,207 4,011 2,326 21,218 23,544 ( 8,424 ) 2001-2003 2007-2010 39
Mt. Carmel East Columbus, OH — — 14,983 409 — 15,392 15,392 ( 570 ) 1991 2001 39
Olentangy Columbus, OH — 1,247 9,830 1,001 1,247 10,831 12,078 ( 1,425 ) 1985 2019 39
Polaris MOB Columbus, OH — 1,447 12,192 66 1,447 12,258 13,705 ( 2,315 ) 2012 2016 39
Gahanna MOB Gahanna, OH — 1,078 5,674 59 1,078 5,733 6,811 ( 1,322 ) 1997 2016 30
Hilliard II MOB Hilliard, OH — 959 7,260 288 959 7,548 8,507 ( 1,553 ) 2014 2016 38
Hilliard MOB Hilliard, OH — 946 11,174 743 946 11,917 12,863 ( 2,965 ) 2013 2015 39
Park Place MOP Kettering, OH — 1,987 11,341 5,411 1,987 16,752 18,739 ( 7,385 ) 1998-2002 2007 39
Liberty Falls MP Liberty, OH — 842 5,640 836 842 6,476 7,318 ( 2,695 ) 2008 2008 39
Parma Ridge MOB Parma, OH — 372 3,636 1,006 372 4,642 5,014 ( 2,005 ) 1977 2008 39
St. Ann's MOB Westerville, OH — — 16,978 8 — 16,986 16,986 ( 793 ) 2004 2020 39
Deaconess MOP Oklahoma City, OK — — 25,975 2,938 — 28,913 28,913 ( 10,795 ) 1991-1996 2008 39
Silverton Health MOB Woodburn, OR — 953 6,164 ( 27 ) 953 6,137 7,090 ( 1,150 ) 2001 2016 35
Monroeville MOB Monroeville, PA — 3,264 7,038 1,453 3,264 8,491 11,755 ( 2,994 ) 1985-1989 2013 39
113
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
SCHEDULE III — REAL ESTATE AND ACCUMULATED DEPRECIATION — (Continued)
Initial Cost to Company Cost
Capitalized
Subsequent
to
Acquisition (a) Gross Amount at Which
Carried at Close of Period
Encumbrances Land Buildings,
Improvements and
Fixtures Land Buildings,
Improvements and
Fixtures Total (c) Accumulated
Depreciation (f)
Date of Construction Date
Acquired Life on Which Building Depreciation in Income Statement is Computed (h)
2750 Monroe MOB Norristown, PA $ — $ 2,323 $ 22,631 $ 5,423 $ 2,323 $ 28,054 $ 30,377 $ ( 12,984 ) 1985 2007 39
1740 South MOB Philadelphia, PA — 1,855 7,735 241 1,855 7,976 9,831 ( 726 ) 1986 2019 39
Main Line Bryn Mawr MOB Philadelphia, PA — — 46,967 5,095 — 52,062 52,062 ( 6,077 ) 2017 2017 39
Phoenixville MOBs Phoenixville, PA — — 60,287 — — 60,287 60,287 ( 295 ) 1991-2008 2021 39
Federal North MOB Pittsburgh, PA — 2,489 30,268 4,463 2,489 34,731 37,220 ( 10,290 ) 1999 2010 39
Highmark Penn Ave Pittsburgh, PA — 1,774 38,921 865 1,774 39,786 41,560 ( 11,141 ) 1907-1998 2012 39
WP Allegheny HQ MOB Pittsburgh, PA — 1,514 32,368 3,669 1,514 36,037 37,551 ( 11,020 ) 2002 2010 39
39 Broad Street Charleston, SC — 3,180 1,970 3,161 3,480 4,831 8,311 ( 1,249 ) 1891 2015 39
Cannon Park Place Charleston, SC — 425 8,651 942 425 9,593 10,018 ( 3,284 ) 1998 2010 39
MUSC Elm MOB Charleston, SC — 1,172 4,361 178 1,172 4,539 5,711 ( 978 ) 2015 2016 39
Tides Medical Arts Center Charleston, SC — 3,763 19,787 411 3,763 20,198 23,961 ( 4,347 ) 2007 2014 39
Bowman Center Mt. Pleasant, SC — 3,896 6,874 — 3,896 6,874 10,770 ( 67 ) 2001 2021 39
East Cooper Medical Arts Center Mt. Pleasant, SC — 2,470 6,289 ( 290 ) 2,470 5,999 8,469 ( 1,630 ) 2001 2014 32
East Cooper Medical Center Mt. Pleasant, SC — 2,073 5,939 2,594 2,073 8,533 10,606 ( 2,904 ) 1992 2010 39
The Mullis Building Mt. Pleasant, SC — — 18,810 48 — 18,858 18,858 ( 401 ) 2016 2021 39
MUSC University MOB North Charleston, SC — 1,524 9,627 ( 882 ) 1,524 8,745 10,269 ( 1,615 ) 2006 2015 36
St. Thomas DePaul MOB Murfreesboro, TN — — 55,040 1,003 — 56,043 56,043 ( 7,320 ) 2008 2017 39
Amarillo Hospital Amarillo, TX — 1,110 17,688 605 1,110 18,293 19,403 ( 6,618 ) 2007 2008 39
Austin Heart MOB Austin, TX — — 15,172 612 — 15,784 15,784 ( 4,138 ) 1999 2013 39
BS&W MOBs Austin, TX — — 300,952 1,657 — 302,609 302,609 ( 39,353 ) 2009-2016 2017 39
Post Oak North MC Austin, TX — 887 7,011 ( 221 ) 887 6,790 7,677 ( 1,585 ) 2007 2013 39
MatureWell MOB Bryan, TX — 1,307 11,078 — 1,307 11,078 12,385 ( 1,858 ) 2016 2017 39
Texas A&M Health Science Center Bryan, TX — — 32,494 ( 2,009 ) — 30,485 30,485 ( 7,374 ) 2011 2013 39
Dallas Rehab Hospital Carrollton, TX — 1,919 16,341 ( 505 ) 1,919 15,836 17,755 ( 5,067 ) 2006 2010 39
Cedar Hill MOB Cedar Hill, TX — 778 4,830 1,898 778 6,728 7,506 ( 2,243 ) 2007 2008 39
Cedar Park MOB Cedar Park, TX — — 30,338 1,268 — 31,606 31,606 ( 4,212 ) 2007 2017 39
Corsicana MOB Corsicana, TX — — 6,781 233 — 7,014 7,014 ( 2,593 ) 2007 2009 39
Dallas LTAC Hospital Dallas, TX — 2,301 20,627 — 2,301 20,627 22,928 ( 6,996 ) 2007 2009 39
Forest Park Pavilion Dallas, TX — 9,670 11,152 48,094 9,670 59,246 68,916 ( 3,732 ) 2010-2021 2012-2021 39
Forest Park Tower Dallas, TX — 3,340 35,071 5,841 3,340 40,912 44,252 ( 10,289 ) 2011 2013 39
Northpoint Medical Dallas, TX — 2,388 14,621 1,629 2,388 16,250 18,638 ( 3,496 ) 2017 2017 20
Baylor MOBs Dallas/Fort Worth, TX — 9,956 122,852 6,737 9,956 129,589 139,545 ( 16,761 ) 2013-2017 2017 39
Denton Med Rehab Hospital Denton, TX — 2,000 11,704 — 2,000 11,704 13,704 ( 4,444 ) 2008 2009 39
Denton MOB Denton, TX — — 7,543 733 — 8,276 8,276 ( 2,567 ) 2000 2010 39
Cliff Medical Plaza MOB El Paso, TX — 1,064 1,972 4,157 1,064 6,129 7,193 ( 3,023 ) 1977 2016 8
El Paso MOB El Paso, TX — 2,075 14,902 ( 233 ) 2,075 14,669 16,744 ( 1,207 ) 1994-2008 2019 39
Providence Medical Plaza El Paso, TX — — 5,396 4,080 — 9,476 9,476 ( 2,906 ) 1981 2016 20
Sierra Medical El Paso, TX — — 2,998 1,011 — 4,009 4,009 ( 1,616 ) 1972 2016 15
114
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
SCHEDULE III — REAL ESTATE AND ACCUMULATED DEPRECIATION — (Continued)
Initial Cost to Company Cost
Capitalized
Subsequent
to
Acquisition (a) Gross Amount at Which
Carried at Close of Period
Encumbrances Land Buildings,
Improvements and
Fixtures Land Buildings,
Improvements and
Fixtures Total (c) Accumulated
Depreciation (f)
Date of Construction Date
Acquired Life on Which Building Depreciation in Income Statement is Computed (h)
Texas Tech MOB El Paso, TX $ — $ — $ 42,419 $ 2,040 $ — $ 44,459 $ 44,459 $ ( 1,178 ) 2017 2020 39
Texas Health MOB Fort Worth, TX — — 38,429 165 — 38,594 38,594 ( 5,282 ) 2014 2017 39
Forest Park Frisco MC Frisco, TX — 1,238 19,979 9,038 1,238 29,017 30,255 ( 9,851 ) 2012 2013 39
T-Mobile Building Frisco, TX — 4,807 67,076 ( 3,139 ) 4,807 63,937 68,744 ( 7,827 ) 2014 2017 38
Greenville MOB Greenville, TX — 616 10,822 633 616 11,455 12,071 ( 4,172 ) 2007 2008 39
7900 Fannin MOB Houston, TX — — 34,764 2,767 — 37,531 37,531 ( 11,942 ) 2005 2010 39
Cypress Medical Building MOB Houston, TX — — 4,678 203 — 4,881 4,881 ( 1,273 ) 1984 2016 30
Cypress Station MOB Houston, TX — 1,345 8,312 ( 4,237 ) 1,345 4,075 5,420 ( 3,644 ) 1981 2008 39
Gemini MOB Houston, TX — 4,619 17,450 153 4,619 17,603 22,222 ( 1,410 ) 1985-1986 2019 39
Houston Medical Plaza Houston, TX — 4,107 35,560 36 4,110 35,593 39,703 ( 363 ) 1983 2021 39
Park Plaza MOB Houston, TX — 5,719 50,054 8,389 5,719 58,443 64,162 ( 15,664 ) 1984 2016 24
T-Mobile Tower Houston, TX — 8,314 15,335 35 8,314 15,370 23,684 ( 419 ) 1974 2021 39
Triumph Hospital NW Houston, TX — 1,377 14,531 164 1,377 14,695 16,072 ( 5,819 ) 1986 2007 39
Memorial Hermann MOBs Humble, TX — — 9,479 13,361 — 22,840 22,840 ( 3,130 ) 1993 2017 25-39
Jourdanton MOB Jourdanton, TX — — 17,804 2 — 17,806 17,806 ( 2,384 ) 2013 2017 39
Houston Methodist MOBs Katy, TX — — 43,078 7,760 — 50,838 50,838 ( 5,641 ) 2001-2006 2017 35-39
Lone Star Endoscopy MOB Keller, TX — 622 3,502 36 622 3,538 4,160 ( 1,330 ) 2006 2008 39
Seton Medical MOB Kyle, TX — — 30,102 2,617 — 32,719 32,719 ( 4,470 ) 2009 2017 39
Lewisville MOB Lewisville, TX — 452 3,841 ( 133 ) 452 3,708 4,160 ( 1,219 ) 2000 2010 39
Longview Regional MOBs Longview, TX — — 59,258 — — 59,258 59,258 ( 8,209 ) 2003-2015 2017 36-39
Terrace Medical Building Nacogdoches, TX — — 179 121 — 300 300 ( 154 ) 1975 2016 5
Towers Medical Plaza Nacogdoches, TX — — 786 236 — 1,022 1,022 ( 617 ) 1981 2016 10
North Cypress MOBs North Cypress/Houston, TX — 7,841 121,215 1,687 7,841 122,902 130,743 ( 16,639 ) 2006-2015 2017 35-39
Pearland MOB Pearland, TX — 912 4,628 314 912 4,942 5,854 ( 1,732 ) 2003-2007 2010 39
Independence Medical Village Plano, TX — 4,229 17,874 ( 132 ) 4,229 17,742 21,971 ( 3,347 ) 2014 2016 39
San Angelo MOB San Angelo, TX — — 3,907 ( 237 ) — 3,670 3,670 ( 1,331 ) 2007 2009 39
Mtn Plains Pecan Valley San Antonio, TX — 416 13,690 512 416 14,202 14,618 ( 5,091 ) 1998 2008 39
Sugar Land II MOB Sugar Land, TX — — 9,648 79 — 9,727 9,727 ( 3,198 ) 1999 2010 39
Triumph Hospital SW Sugar Land, TX — 1,670 14,018 ( 670 ) 1,656 13,362 15,018 ( 5,625 ) 1989 2007 39
Mtn Plains Clear Lake Webster, TX — 832 21,168 5,761 832 26,929 27,761 ( 8,382 ) 2006 2008 39
N. Texas Neurology MOB Wichita Falls, TX — 736 5,611 ( 1,957 ) 736 3,654 4,390 ( 1,838 ) 1957 2008 39
Wylie Medical Plaza Wylie, TX — 1,412 15,353 272 1,412 15,625 17,037 ( 1,205 ) 2013 2020 39
Renaissance MC Bountiful, UT — 3,701 24,442 442 3,701 24,884 28,585 ( 8,850 ) 2004 2008 39
Salt Lake Regional Medical Building Salt Lake City, UT — — 10,351 110 — 10,461 10,461 ( 670 ) 1989 2020 39
Fairfax MOB Fairfax, VA — 2,404 14,074 193 2,404 14,267 16,671 ( 1,379 ) 1959 2019 39
Fair Oaks MOB Fairfax, VA — — 47,616 562 — 48,178 48,178 ( 5,876 ) 2009 2017 39
Aurora - Menomonee Menomonee Falls, WI — 1,055 14,998 — 1,055 14,998 16,053 ( 6,816 ) 1964 2009 39
Aurora - Milwaukee Milwaukee, WI — 350 5,508 — 350 5,508 5,858 ( 2,508 ) 1983 2009 39
Columbia St. Mary's MOBs Milwaukee, WI — — 87,825 1,144 — 88,969 88,969 ( 10,921 ) 1994-2007 2017 35-39
$ — $ 612,952 $ 6,155,907 $ 566,865 $ 619,820 $ 6,715,906 $ 7,335,726 $ ( 1,401,742 )
115
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
SCHEDULE III — REAL ESTATE AND ACCUMULATED DEPRECIATION — (Continued)
Initial Cost to Company Cost
Capitalized
Subsequent
to
Acquisition (a) Gross Amount at Which
Carried at Close of Period
Encumbrances Land Buildings,
Improvements and
Fixtures Land Buildings,
Improvements and
Fixtures Total (c) Accumulated
Depreciation (f)
Date of Construction Date
Acquired Life on Which Building Depreciation in Income Statement is Computed (h)
Undeveloped land:
Macon Pond MOB Raleigh, NC $ — $ 5,504 $ — $ 13 $ 5,504 $ 13 $ 5,517 $ — N/A 2021 N/A
Forest Park Pavilion IV Dallas, TX — 7,014 — — 7,014 — 7,014 — N/A 2019 N/A
Houston Heights Houston, TX — 10,445 — 5 10,445 5 10,450 — N/A 2020 N/A
$ — $ 22,963 $ — $ 18 $ 22,963 $ 18 $ 22,981 $ —
Real estate held for sale $ — $ ( 2,401 ) $ ( 39,693 ) $ 12,285 ( 2,401 ) ( 27,408 ) ( 29,809 ) $ 6,263
Total $ — $ 633,514 $ 6,116,214 $ 579,168 $ 640,382 $ 6,688,516 $ 7,328,898 $ ( 1,395,479 )
(a) The cost capitalized subsequent to acquisition is net of dispositions or other write-downs and impairment.
(b) The above table excludes lease intangibles; see notes (d) and (g).
(c) The changes in total real estate for the years ended December 31, 2021, 2020 and 2019 are as follows (in thousands):
Year Ended December 31,
2021 2020 2019
Balance as of the beginning of the year $ 7,104,085 $ 6,837,400 $ 6,269,023
Acquisitions 278,124 171,728 505,424
Additions 188,592 121,777 90,859
Dispositions and other ( 189,156 ) ( 26,820 ) ( 27,906 )
Impairment ( 22,938 ) — —
Held for sale ( 29,809 ) — —
Balance as of the end of the year (d) $ 7,328,898 $ 7,104,085 $ 6,837,400
(d) The balances as of December 31, 2021, 2020 and 2019 exclude gross lease intangibles of $ 404.7 million, $ 628.6 million and $ 628.1 million, respectively.
(e) The aggregate cost of our real estate for federal income tax purposes was $ 6.9 billion.
(f) The changes in accumulated depreciation for the years ended December 31, 2021, 2020 and 2019 are as follows (in thousands):
Year Ended December 31,
2021 2020 2019
Balance as of the beginning of the year $ 1,302,204 $ 1,085,048 $ 882,488
Additions 246,417 236,271 217,566
Dispositions and other ( 146,879 ) ( 19,115 ) ( 15,006 )
Held for sale ( 6,263 ) — —
Balance as of the end of the year (g) $ 1,395,479 $ 1,302,204 $ 1,085,048
(g) The balances as of December 31, 2021, 2020 and 2019 exclude accumulated amortization of lease intangibles of $ 203.0 million, $ 400.5 million and $ 362.8 million, respectively.
(h) Tenant improvements are depreciated over the shorter of the lease term or useful life, ranging from one to 10 years, respectively. Furniture, fixtures and equipment are depreciated over five years .
116
Table of Contents
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
SCHEDULE III — REAL ESTATE AND ACCUMULATED DEPRECIATION — (Continued)
HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE ASSETS
In Thousands
Interest Rate Final Maturity Date Payment Terms Prior Liens Face Amount Carrying Amount Principal Amount of Loans Subject to Delinquent Principal or Interest
Mortgage loan on real estate located in:
Texas 10.00 % 7/1/2022 (1) $ — $ 15,000 $ 14,267 $ —
Mezzanine loans on real estate located in:
Texas 8.00 % 6/24/2024 (2) — 49,319 48,793 —
North Carolina 8.00 % 12/22/2024 (3) — 6,000 6,012 —
Total real estate notes receivable $ — $ 70,319 $ 69,072 $ —
Accrued interest receivable — — 42 —
Total real estate notes receivable, net $ — $ 70,319 $ 69,114 $ —
(1) Twelve-month prefunded interest reserve, with principal sum and interest on unpaid principal due on the maturity date.
(2) Interest is accrued and funded utilizing interest reserves, funded through payment-in-kind interest, until such time the interest reserve is fully funded. Thereafter, interest only payments due with principal and any unpaid interest due on the maturity date.
(2) Capitalized interest through maturity, with outstanding principal and accrued interest due on the maturity date.
The following shows changes in the carrying amounts of mortgage loans on real estate assets during the years ended December 31, 2021, 2020 and 2019 (in thousands):
Year Ended December 31,
2021 2020 2019
Balance as of the beginning of the year $ 555 $ 1,332 $ 2,070
Additions:
New real estate notes 67,032 6,000 —
Capitalized interest 1,841 — —
Accretion of fees and other items 932 — —
Deductions:
Mortgage loan retired in connection with an acquisition — ( 6,000 ) —
Collection of real estate loans ( 555 ) ( 777 ) ( 738 )
Deferred fees and other items ( 691 ) — —
Balance as of the end of the year $ 69,114 $ 555 $ 1,332
117
Table of Contents
EXHIBIT INDEX
Pursuant to Item 601(a)(2) of Regulation S-K, this Exhibit Index immediately precedes the exhibits.
The following exhibits are included, or incorporated by reference, in this Annual Report for the fiscal year ended December 31, 2021 (and are numbered in accordance with Item 601 of Regulation S-K).
1.1 Underwriting Agreement, dated May 2, 2017, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, on the one hand, and Wells Fargo Securities, LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein, on the other hand (included as Exhibit 1.1 to our Current Report on Form 8-K filed on May 8, 2017 and incorporated herein by reference).
1.2 Underwriting Agreement, dated June 1, 2017, among Healthcare Trust of America Holdings, LP, Healthcare Trust of America, Inc., and Wells Fargo Securities, LLC, J.P. Morgan Securities LLC and U.S. Bancorp Investments, Inc., as representatives of the several underwriters named therein (included as Exhibit 1.1 to our Current Report on Form 8-K filed on June 7, 2017 and incorporated herein by reference).
1.3 Underwriting Agreement, dated September 5, 2019, among Healthcare Trust of America Holdings, LP, Healthcare Trust of America, Inc., and BofA Securities, Inc., J.P. Morgan Securities LLC, U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (included as Exhibit 1.1 to our Current Report on Form 8-K filed on September 6, 2019 and incorporated herein by reference).
1.4 Underwriting Agreement, dated September 14, 2020, among Healthcare Trust of America Holdings, LP, Healthcare Trust of America, Inc., and Wells Fargo Securities, LLC, Jefferies LLC, J.P. Morgan Securities LLC, and U.S. Bancorp Investments, Inc. as representatives of the several underwriters named therein (included as Exhibit 1.1 to our Current Report on Form 8-K filed on September 15, 2020 and incorporated herein by reference).
1.5 Equity Distribution Agreement, dated March 5, 2021, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, on the one hand, and J.P. Morgan Securities LLC and JPMorgan Chase Bank, National Association, on the other hand (included as Exhibit 1.1 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.6 Equity Distribution Agreement, dated March 5, 2021, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, on the one hand, and BMO Capital Markets Corp. and Bank of Montreal, on the other hand (included as Exhibit 1.2 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.7 Equity Distribution Agreement, dated March 5, 2021, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, on the one hand, and MUFG Securities Americas Inc. and MUFG Securities EMEA plc, on the other hand (included as Exhibit 1.3 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.8 Equity Distribution Agreement, dated March 5, 2021, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, on the one hand, and Wells Fargo Securities, LLC and Wells Fargo Bank, National Association, on the other hand (included as Exhibit 1.4 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.9 Equity Distribution Agreement, dated March 5, 2021, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, on the one hand, and BofA Securities, Inc. and Bank of America, N.A., on the other hand (included as Exhibit 1.5 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.10 Equity Distribution Agreement, dated March 5, 2021, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, on the one hand, and Jefferies LLC, on the other hand (included as Exhibit 1.6 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.11 Equity Distribution Agreement, dated March 5, 2021, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, on the one hand, and Morgan Stanley & Co. LLC, on the other hand (included as Exhibit 1.7 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.12 Equity Distribution Agreement, dated March 5, 2021, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, on the one hand, and Capital One Securities, Inc., on the other hand (included as Exhibit 1.8 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.13 Equity Distribution Agreement, dated March 5, 2021, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, on the one hand, and BTIG, LLC, on the other hand (included as Exhibit 1.9 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.14 Equity Distribution Agreement, dated March 5, 2021, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, on the one hand, and Scotia Capital (USA) Inc. and the Bank of Nova Scotia, on the other hand (included as Exhibit 1.10 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
118
Table of Contents
1.15 Master Forward Confirmation, dated March 5, 2021, between Healthcare Trust of America, Inc. and JPMorgan Chase Bank, National Association (included as Exhibit 1.11 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.16 Master Forward Confirmation, dated March 5, 2021, between Healthcare Trust of America, Inc. and Bank of Montreal (included as Exhibit 1.12 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.17 Master Forward Confirmation, dated March 5, 2021, between Healthcare Trust of America, Inc. and MUFG Securities EMEA plc. (included as Exhibit 1.13 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.18 Master Forward Confirmation, dated March 5, 2021, between Healthcare Trust of America, Inc. and Wells Fargo Bank, National Association (included as Exhibit 1.14 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.19 Master Forward Confirmation, dated March 5, 2021, between Healthcare Trust of America, Inc. and Bank of America, N.A. (included as Exhibit 1.15 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.20 Master Forward Confirmation, dated March 5, 2021, between Healthcare Trust of America, Inc. and Jefferies LLC (included as Exhibit 1.16 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.21 Master Forward Confirmation, dated March 5, 2021, between Healthcare Trust of America, Inc. and Morgan Stanley & Co. LLC (included as Exhibit 1.17 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
1.22 Master Forward Confirmation, dated March 5, 2021, between Healthcare Trust of America, Inc. and The Bank of Nova Scotia (included as Exhibit 1.18 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
2.1 Agreement and Plan of Merger, dated as of February 28, 2022, among Healthcare Realty Trust Incorporated, Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, and HR Acquisition 2, LLC (included as Exhibit 2.1 to our Current Report on Form 8-K filed on March 1, 2022 and incorporated herein by reference).
3.1 Fifth Articles of Amendment and Restatement of Healthcare Trust of America, Inc., effective March 11, 2014 (included as Exhibit 3.1 to our Current Report on Form 8-K filed on March 11, 2014 and incorporated herein by reference).
3.2 Articles of Amendment of Healthcare Trust of America, Inc., effective December 15, 2014 (included as Exhibit 3.1 to our Current Report on Form 8-K filed on December 16, 2014 and incorporated herein by reference).
3.3 Articles of Amendment of Healthcare Trust of America, Inc., effective December 15, 2014 (included as Exhibit 3.2 to our Current Report on Form 8-K filed on December 16, 2014 and incorporated herein by reference).
3.4 Certificate of Limited Partnership of NNN Healthcare/Office REIT Holdings, L.P. (included as Exhibit 3.3 to our Registration Statement on Form S-4 (File No. 333-190916) filed on August 30, 2013 and incorporated herein by reference).
3.5 Certificate of Correction to Certificate of Limited Partnership of NNN Healthcare/Office REIT Holdings, L.P. (included as Exhibit 3.4 to our Registration Statement on Form S-4 (File No. 333-190916) filed on August 30, 2013 and incorporated herein by reference).
3.6 Certificate of Amendment to Certificate of Limited Partnership of NNN Healthcare/Office REIT Holdings, L.P. (included as Exhibit 3.5 to our Registration Statement on Form S-4 (File No. 333-190916) filed on August 30, 2013 and incorporated herein by reference).
3.7 Amendment to the Certificate of Limited Partnership of NNN Healthcare/Office REIT Holdings, L.P. (included as Exhibit 3.6 to our Registration Statement on Form S-4 (File No. 333-190916) filed on August 30, 2013 and incorporated herein by reference).
3.8 Certificate of Amendment to Certificate of Limited Partnership of Grubb & Ellis Healthcare REIT Holdings, LP. (included as Exhibit 3.7 to our Registration Statement on Form S-4 (File No. 333-190916) filed on August 30, 2013 and incorporated herein by reference).
3.9 Certificate of Amendment to Certificate of Limited Partnership of Healthcare Trust of America Holdings, LP (included as Exhibit 3.8 to our Registration Statement on Form S-4 (File No. 333-190916) filed on August 30, 2013 and incorporated herein by reference).
3.10 Amended and Restated Agreement of Limited Partnership of Healthcare Trust of America Holdings, LP (included as Exhibit 10.1 to our Current Report on Form 8-K filed on December 21, 2012 and incorporated herein by reference).
3.11 Articles Supplementary of Healthcare Trust of America, Inc., dated July 14, 2017 (included as Exhibit 3.1 to our Current Report on Form 8-K filed on July 14, 2017 and incorporated herein by reference).
119
Table of Contents
3.12 Fourth Amended and Restated Bylaws of Healthcare Trust of America, Inc., dated April 27, 2020 (included as Exhibit 3.1 to our Current Report on Form 8-K filed on April 29, 2020 and incorporated herein by reference.
4.1 Indenture, dated as of March 28, 2013, among Healthcare Trust of America Holdings, LP, Healthcare Trust of America, Inc. and U.S. Bank National Association, as trustee, including the form of 3.70% Senior Notes due 2023 and the guarantee thereof (included as Exhibit 4.1 to our Current Report on Form 8-K filed on March 28, 2013 and incorporated herein by reference).
4.2 2026 Notes Indenture, dated as of July 12, 2016, among Healthcare Trust of America Holdings, LP, Healthcare Trust of America, Inc. and U.S. Bank National Association, as trustee, including the form of 3.500% Senior Notes due 2026 and the guarantee thereof (included as Exhibit 4.1 to the Operating Partnership’s Current Report on Form 8-K filed on July 12, 2016 and incorporated herein by reference).
4.2 2027 Notes Indenture, dated as of June 8, 2017, among Healthcare Trust of America Holdings, LP, Healthcare Trust of America, Inc. and U.S. Bank National Association, as trustee, including the form of 3.750% Senior Notes due 2027 and the guarantee thereof (included as Exhibit 4.2 to our Current Report on Form 8-K filed on June 13, 2017 and incorporated herein by reference).
4.3 2030 Notes Indenture, dated as of September 16, 2019, among Healthcare Trust of America Holdings, LP, Healthcare Trust of America, Inc. and U.S. Bank National Association, as trustee, including the form of 3.100% Senior Notes due 2030 and the guarantee thereof (included as Exhibit 4.1 to our Current Report on Form 8-K filed on September 16, 2019 and incorporated by reference).
4.4 2031 Notes Indenture, dated as of September 28, 2020, among Healthcare Trust of America Holdings, LP, Healthcare Trust of America, Inc. and U.S. Bank National Association, as trustee, including the form of 2.000% Senior Notes due 2031 and the guarantee thereof (included as Exhibit 4.1 to our Current Report on Form 8-K filed on September 28, 2020 and incorporated herein by reference).
4.5* Description of Registrant's Securities.
5.1 Opinion of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on September 13, 2016 and incorporated herein by reference).
5.2 Opinion of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on May 8, 2017 and incorporated herein by reference).
5.3 Opinion of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on June 13, 2017 and incorporated herein by reference).
5.4 Opinion of O’Melveny & Myers LLP (included as Exhibit 5.2 to our Current Report on Form 8-K filed on June 13, 2017 and incorporated herein by reference).
5.5 Opinion of O’Melveny & Myers LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on September 18, 2017 and incorporated herein by reference).
5.6 Opinion of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on December 28, 2018 and incorporated herein by reference).
5.7 Opinion of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on September 16, 2019 and incorporated herein by reference).
5.8 Opinion of O’Melveny & Myers LLP (included as Exhibit 5.2 to our Current Report on Form 8-K filed on September 16, 2019 and incorporated herein by reference).
5.9 Opinion of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on November 29, 2019 and incorporated herein by reference).
5.10 Opinion of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on September 28, 2020 and incorporated herein by reference).
5.11 Opinion of McDermott Will & Emery LLP (included as Exhibit 5.2 to our Current Report on Form 8-K filed on September 28, 2020 and incorporated herein by reference).
5.12 Opinion of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
8.1 Opinion of O’Melveny & Myers LLP as to certain tax matters (included as Exhibit 8.1 to our Current Report on Form 8-K filed on May 8, 2017 and incorporated herein by reference).
8.2 Opinion of O’Melveny & Myers LLP as to certain tax matters (included as Exhibit 8.1 to our Current Report on Form 8-K filed on June 13, 2017 and incorporated herein by reference).
8.3 Opinion of O’Melveny & Myers LLP as to certain tax matters (included as Exhibit 8.1 to our Current Report on Form 8-K filed on September 16, 2019 and incorporated herein by reference).
8.4 Opinion of McDermott Will & Emery LLP as to certain tax matters (included as Exhibit 8.1 to our Current Report on Form 8-K filed on September 28, 2020 and incorporated herein by reference).
10.1 Agreement Representing Indemnification Matters, dated February 22, 2021 (included as Exhibit 10.1 to our Annual Report on Form 10-K filed on February 24, 202 1 and incorporated herein by reference).
120
Table of Contents
10.2 Form of Indemnification Agreement executed by Jay P. Leupp (included as Exhibit 10.2 to our Annual Report on Form 10-K filed on February 18, 2020 and incorporated herein by reference).
10.3 Form of Indemnification Agreement executed by Vicki U. Booth (included as Exhibit 10.1 to our Annual Report on Form 10-K filed on February 19, 2019 and incorporated herein by reference).
10.4 Form of Indemnification Agreement executed by Roberta B. Bowman (included as Exhibit 10.2 to our Annual Report on Form 10-K filed on February 19, 2019 and incorporated herein by reference).
10.5 Form of Indemnification Agreement executed by Daniel S. Henson (included as Exhibit 10.3 to our Annual Report on Form 10-K filed on February 19, 2019 and incorporated herein by reference).
10.6† Healthcare Trust of America, Inc. Amended and Restated 2006 Incentive Plan, dated February 24, 2011 (included as Exhibit 10.1 to our Current Report on Form 8-K filed on March 2, 2011 and incorporated herein by reference).
10.7† Healthcare Trust of America, Inc. 2006 Independent Directors Compensation Plan, effective as of July 9, 2019 (included as Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on July 24, 2019 and incorporated herein by reference).
10.8 Form of Amended and Restated Indemnification Agreement executed by Scott D. Peters, W. Bradley Blair, II, Maurice J. DeWald, Warren D. Fix, Larry L. Mathis and Gary T. Wescombe (included as Exhibit 10.1 to our Current Report on Form 8-K filed on December 22, 2010 and incorporated herein by reference).
10.9 Form of Indemnification Agreement executed by Amanda L. Houghton (included as Exhibit 10.49 to our Annual Report on Form 10-K filed on March 1, 2013 and incorporated herein by reference).
10.10 Form of Indemnification Agreement executed by Robert A. Milligan (included as Exhibit 10.50 to our Annual Report on Form 10-K filed on March 1, 2013 and incorporated herein by reference).
10.11 Form of Indemnification Agreement executed by Peter N. Foss (included as Exhibit 10.2 to our Quarterly Report on Form 10-Q filed on July 30, 2015 and incorporated herein by reference).
10.12 Form of LTIP Award Agreement (CEO Version) (included as Exhibit 10.2 to our Current Report on Form 8-K filed on May 18, 2012 and incorporated herein by reference).
10.13 Form of LTIP Award Agreement (Executive Version) (included as Exhibit 10.3 to our Current Report on Form 8-K filed on May 18, 2012 and incorporated herein by reference).
10.14 Form of LTIP Award Agreement (Director Version) (included as Exhibit 10.4 to our Current Report on Form 8-K filed on May 18, 2012 and incorporated herein by reference).
10.15† Amended and Restated Employment Agreement between Healthcare Trust of America, Inc. and Scott D. Peters, effective July 8, 2016 (included as Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on August 3, 2016 and incorporated herein by reference).
10.16† Amended and Restated Employment Agreement between Healthcare Trust of America, Inc. and Robert A. Milligan, effective July 8, 2016 (included as Exhibit 10.2 to our Quarterly Report on Form 10-Q filed on August 3, 2016 and incorporated herein by reference).
10.17† Amended and Restated Employment Agreement between Healthcare Trust of America, Inc. and Amanda L. Houghton, effective July 8, 2016 (included as Exhibit 10.4 to our Quarterly Report on Form 10-Q filed on August 2, 2016 and incorporated herein by reference).
10.18 Letter Agreement between Healthcare Trust of America, Inc. and Scott D. Peters dated July 14, 2017 (included as Exhibit 10.1 to our Current Report on Form 8-K filed on July 14, 2017 and incorporated herein by reference).
10.19 Letter Agreement between Healthcare Trust of America, Inc. and Robert A. Milligan dated July 14, 2017 (included as Exhibit 10.2 to our Current Report on Form 8-K filed on July 14, 2017 and incorporated herein by reference).
10.20 Letter Agreement between Healthcare Trust of America, Inc. and Amanda L. Houghton dated July 14, 2017 (included as Exhibit 10.3 to our Current Report on Form 8-K filed on July 14, 2017 and incorporated herein by reference).
10.21 Letter Agreement between Healthcare Trust of America, Inc. and Scott D. Peters dated March 18, 2019 (included as Exhibit 10.1 to our Current Report on Form 8-K filed on March 18, 2019 and incorporated herein by reference).
10.22 Letter Agreement between Healthcare Trust of America, Inc. and Robert A. Milligan dated March 18, 2019 (included as Exhibit 10.2 to our Current Report on Form 8-K filed on March 18, 2019 and incorporated herein by reference).
10.23 Letter Agreement between Healthcare Trust of America, Inc. and Amanda L. Houghton dated March 18, 2019 (included as Exhibit 10.3 to our Current Report on Form 8-K filed on March 18, 2019 and incorporated herein by reference).
10.24 Restricted Stock Award Certificate (included as Exhibit 10.27 to our Annual Report on Form 10-K filed on February 21, 2017 and incorporated herein by reference).
121
Table of Contents
10.25 Credit Agreement by and among Healthcare Trust of America Holdings, LP, Healthcare Trust of America, Inc., JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, N.A. and Deutsche Bank Securities Inc., as syndication agents, U.S. Bank National Association, Fifth Third Bank, Capital One, N.A., Regions Bank, and Compass Bank, as documentation agents, and the Lenders Party Hereto dated March 29, 2012 (included as Exhibit 10.1 to our Current Report on Form 8-K filed on April 2, 2012 and incorporated herein by reference).
10.26 Guaranty by Healthcare Trust of America, Inc. for the benefit of JPMorgan Chase Bank, N.A., as administrative agent, the Lenders, the Issuing Bank and the Swingline Lender dated March 29, 2012 (included as Exhibit 10.2 to our Current Report on Form 8-K filed on April 2, 2012 and incorporate herein by reference).
10.27 Credit Agreement by and among Healthcare Trust of America Holdings, LP, Wells Fargo Bank, N.A., as administrative agent, Wells Fargo Securities, LLC, as lead arranger, and the Lenders Party Hereto, dated July 20, 2012 (included as Exhibit 10.8 to our Quarterly Report on Form 10-Q filed on August 9, 2012 and incorporated herein by reference).
10.28 Guaranty by Healthcare Trust of America, Inc. in favor of Wells Fargo Bank, N.A., as administrative agent dated July 20, 2012 (included as Exhibit 10.9 to our Quarterly Report on Form 10-Q filed on August 9, 2012 and incorporated herein by reference).
10.29 Term Loan Note (included as Exhibit 10.2 to our Current Report on Form 8-K filed on January 9, 2014 and incorporated herein by reference).
10.30 First Modification to Credit Agreement (included as Exhibit 10.3 to our Current Report on Form 8-K filed on January 9, 2014 and incorporated herein by reference).
10.31 Amended and Restated Revolving Credit and Term Loan Agreement, dated November 19, 2014, by and among Healthcare Trust of America Holdings, LP, Healthcare Trust of America, Inc., JP Morgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association and U.S. Bank National Association, as syndication agents, Bank of Montreal, PNC Bank, National Association, The Bank of Nova Scotia, and The Bank of Tokyo-Mitsubishi UFJ, Ltd., as documentation agents, Compass Bank, Fifth Third Bank, Regions Bank, and Capital One, N.A., as managing agents and the lenders party thereto (included as Exhibit 10.1 to our Current Report on Form 8-K filed on November 24, 2014 and incorporated herein by reference).
10.32 Guaranty dated November 19, 2014, by Healthcare Trust of America, Inc. for the benefit of JPMorgan Chase Bank, N.A., as administrative agent, the Lenders, and Bank of America, N.A., as swing lender and issuing bank (included as Exhibit 10.2 to our Current Report on Form 8-K filed on November 24, 2014 and incorporated herein by reference).
10.33 Second Modification to Credit Agreement, dated November 19, 2014, by and among Healthcare Trust of America Holdings, LP, Wells Fargo Bank, National Association, and the lenders party thereto (included as Exhibit 10.3 to our Current Report on Form 8-K filed on November 24, 2014 and incorporated herein by reference).
10.34 First Amendment to the Amended and Restated Revolving Credit and Term Loan Agreement, dated February 11, 2015, by and among Healthcare Trust of America, Inc., Healthcare Trust of America Holdings, LP, Bank of America, N.A. and JPMorgan Chase Bank, N.A., as administrative agent for the lenders (included as Exhibit 10.33 to our Annual Report on Form 10-K filed on February 23, 2015 and incorporated herein by reference).
10.35 Third Modification to the Credit Agreement (included as Exhibit 10.1 in our Current Report on Form 8-K filed on September 29, 2016 and incorporated herein by reference).
10.36 Credit Agreement by and among Healthcare Trust of America Holdings, LP, Healthcare Trust of America, Inc., JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association, U.S. Bank National Association, Capital One, N.A., PNC Bank, National Association and Bank of America, N.A., as syndication agents, Bank of Montreal, The Bank of Nova Scotia, The Bank of Tokyo-Mitsubishi UFJ, Ltd., Compass Bank, Fifth Third Bank and Morgan Stanley Senior Funding, Inc., as documentation agents, Regions Bank, as managing agent, and the lenders named therein, dated July 27, 2017 (included as Exhibit 10.1 to our Current Report on Form 8-K filed on July 31, 2017 and incorporated herein by reference).
10.37 Guaranty dated July 27, 2017, by Healthcare Trust of America, Inc. for the benefit of JPMorgan Chase Bank, N.A., as administrative agent, the Lenders, the Issuing Bank and the Swingline Lender (included as Exhibit 10.2 to our Current Report on Form 8-K filed on July 31, 2017 and incorporated herein by reference).
10.38 Fifth Modification to the Credit Agreement, dated August 1, 2018, by and among Healthcare Trust of America Holdings, LP, Wells Fargo, National Association, and the lenders party thereto (included as Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on August 3, 2018 and incorporated herein by reference).
10.39 Form of Indemnification Agreement executed by H. Lee Cooper (included as Exhibit 10.1 to our Annual Report on Form 10-K filed on February 18, 2020 and incorporated herein by reference).
10.40 Agreement Respecting Indemnification Matters, dated November 3, 2020 (included as Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on November 4, 2020 and incorporated herein by reference).
10.41† Healthcare Trust of America, Inc. Amended and Restated 2006 Incentive Plan, dated April 29, 2021 (included as Exhibit 99.1 to our Current Report on Form 8-K filed on July 8, 2021 and incorporated herein by reference).
10.42 Employment Agreement between Healthcare Trust of America, Inc. and Peter N. Foss dated September 16, 2021 (included as Exhibit 10.1 to our Current Report on Form 8-K filed on September 17, 2021 and incorporated herein by reference).
122
Table of Contents
10.43 Credit Agreement by and among Healthcare Trust of America, LP, Healthcare Trust of America, Inc., JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association, U.S. Bank National Association, Capital One, National Association, PNC Bank, National Association and Bank of America, N.A., as syndication agents, Bank of Montreal, The Bank of Nova Scotia, Fifth Third Bank, National Association, Mizuho Bank, LTD., Morgan Stanley Senior Funding, Inc., MUFG Bank, LTD. and Regions Bank, as documentation agents, and the lenders named therein, dated October 6, 2021 (included as Exhibit 10.1 to our Current Report on Form 8-K filed on October 7, 2021 and incorporated herein by reference).
21.1* Subsidiaries.
23.1* Consent of Independent Registered Public Accounting Firm - Healthcare Trust of America, Inc.
23.2* Consent of Independent Registered Public Accounting Firm - Healthcare Trust of America Holdings, LP.
23.3 Consent of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on September 13, 2016 and incorporated herein by reference).
23.4 Consent of KPMG LLP (included as Exhibit 23.1 to our Current Report on Form 8-K filed on May 1, 2017 and incorporated herein by reference).
23.5 Consent of Venable LLP (included as Exhibit 23.1 to our Current Report on Form 8-K filed on May 8, 2017 and incorporated herein by reference).
23.6 Consent of O’Melveny & Myers LLP as to certain tax matters (included as Exhibit 23.2 to our Current Report on Form 8-K filed on May 8, 2017 and incorporated herein by reference).
23.7 Consent of Venable LLP (included as Exhibit 23.1 to our Current Report on Form 8-K filed on June 13, 2017 and incorporated herein by reference).
23.8 Consent of O’Melveny & Myers LLP (included as Exhibit 5.2 and 8.1 to our Current Report on Form 8-K filed on June 13, 2017 and incorporated herein by reference).
23.9 Consent of KPMG LLP (included as Exhibit 23.1 to our Current Report on Form 8-K/A filed on August 21, 2017 and incorporated herein by reference).
23.10 Consent of Katz, Sapper & Miller, LLP (included as Exhibit 23.2 to our Current Report on Form 8-K/A filed on August 21, 2017 and incorporated herein by reference).
23.11 Consent of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on September 18, 2017 and incorporated herein by reference).
23.12 Consent of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on September 16, 2019 and incorporated herein by reference).
23.13 Consent of O’Melveny & Myers LLP (included as Exhibit 5.2 and 8.1 to our Current Report on Form 8-K filed on September 16, 2019 and incorporated herein by reference).
23.14 Consent of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on November 29, 2019 and incorporated herein by reference).
23.15 Consent of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on September 28, 2020 and incorporated herein by reference).
23.16 Consents of McDermott Will & Emery LLP (included as Exhibit 5.2 and 8.1 to our current Report on Form 8-K filed on September 28, 2020 and incorporated herein by reference).
23.17 Consent of Venable LLP (included as Exhibit 5.1 to our Current Report on Form 8-K filed on March 8, 2021 and incorporated herein by reference).
31.1* Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
31.2* Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
31.3* Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
31.4* Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
32.1** Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Inc.
32.2** Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
32.3** Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
32.4** Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
101.INS* Inline XBRL Instance Document.
101.SCH* Inline XBRL Taxonomy Extension Schema Document.
123
Table of Contents
101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
* Filed herewith.
** Furnished herewith.
† Compensatory plan or arrangement.
124
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned thereunto duly authorized.
Healthcare Trust of America, Inc.
By: /s/ Peter N. Foss Interim President and Chief Executive Officer
Peter N. Foss (Principal Executive Officer)
Date: March 1, 2022
By: /s/ Robert A. Milligan Chief Financial Officer
Robert A. Milligan (Principal Financial Officer and Principal Accounting Officer)
Date: March 1, 2022
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
By: /s/ Peter N. Foss Interim President and Chief Executive Officer
Peter N. Foss (Principal Executive Officer)
Date: March 1, 2022
By: /s/ Robert A. Milligan Chief Financial Officer
Robert A. Milligan (Principal Financial Officer and Principal Accounting Officer)
Date: March 1, 2022
By: /s/ W. Bradley Blair, II Lead Director
W. Bradley Blair, II
Date: March 1, 2022
By: /s/ Vicki U. Booth Director
Vicki U. Booth
Date: March 1, 2022
By: /s/ H. Lee Cooper Director
H. Lee Cooper
Date: March 1, 2022
By: /s/ Warren D. Fix Director
Warren D. Fix
Date: March 1, 2022
By: /s/ Jay P. Leupp Director
Jay P. Leupp
Date: March 1, 2022
125
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned thereunto duly authorized.
Healthcare Trust of America Holdings, LP
By: Healthcare Trust of America, Inc.,
its General Partner
By: /s/ Peter N. Foss Interim President and Chief Executive Officer
Peter N. Foss (Principal Executive Officer)
Date: March 1, 2022
By: /s/ Robert A. Milligan Chief Financial Officer
Robert A. Milligan (Principal Financial Officer and Principal Accounting Officer)
Date: March 1, 2022
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
By: /s/ Peter N. Foss Interim President and Chief Executive Officer
Peter N. Foss (Principal Executive Officer) of Healthcare Trust of America, Inc.,
Date: March 1, 2022 general partner of Healthcare Trust of America Holdings, LP
By: /s/ Robert A. Milligan Chief Financial Officer
Robert A. Milligan (Principal Financial Officer and Principal Accounting Officer) of
Date: March 1, 2022 Healthcare Trust of America, Inc., general partner of Healthcare Trust
of America Holdings, LP
By: /s/ W. Bradley Blair, II Lead Director of Healthcare Trust of America, Inc., general partner of
W. Bradley Blair, II Healthcare Trust of America Holdings, LP
Date: March 1, 2022
By: /s/ Vicki U. Booth Director of Healthcare Trust of America, Inc., general partner of
Vicki U. Booth Healthcare Trust of America Holdings, LP
Date: March 1, 2022
By: /s/ H. Lee Cooper Director of Healthcare Trust of America, Inc., general partner of
H. Lee Cooper Healthcare Trust of America Holdings, LP
Date: March 1, 2022
By: /s/ Warren D. Fix Director of Healthcare Trust of America, Inc., general partner of
Warren D. Fix Healthcare Trust of America Holdings, LP
Date: March 1, 2022
By: /s/ Jay P. Leupp Director of Healthcare Trust of America, Inc., general partner of
Jay P. Leupp Healthcare Trust of America Holdings, LP
Date: March 1, 2022
126